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CHAPTER 1.
INTRODUCTION
1.1.

Introduction:
Arguably, one of the most significant discoveries in medicine was the

discovery of penicillin by Alexander Fleming in 1921.1 Since then, antibiotics have
saved millions of lives and by the end of the 1960s the pharmaceutical industry
had stockpiled such a large number of different antibiotics that it was possible to
conclude that mankind had solved the problem of infectious disease.2 However,
almost from the first, resistance to antibiotics was detected in patients.3 At first,
resistance to antibiotics was not a major concern because numerous other
antibiotics were available for use in treating resistant organisms.

Yet, the

continued increase in antibiotic-resistant pathogens has now become so
pronounced that antibiotic resistance threatens to undermine public health. To
demonstrate this, a recent report by Klevens et al. showed that the most common
antibiotic-resistant pathogen, methicillin resistant Staphylococcus aureus (MRSA),
caused approximately 19000 deaths in 2006 in USA.4 This death toll is greater
than that from AIDS in that year. MRSA infections have continued to increase. In
the mid 1970s, MRSA infections constituted only 2% of all infections; yet, three
decades later, MRSA accounts for 63% of Staphylococcus infections.4 In a
separate study conducted

at the Detroit Receiving Hospital,

hospitalization for treating MRSA bacteremia is

the cost of

double that for methicillin-

sensitive Staphylococcus aureus ($21,577 vs. $11,668, respectively).5
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There are three major classes of pathogens that represent the greatest
threat from antibiotic resistance. The first is the multiple-antibiotic-resistant Gram
positive

pathogens,

which

include

MRSA

and

vancomycin-resistant

Staphylococcus aureus (VRSA) strains. Studies have shown that these strains add
an additional three to four billion dollars to the national health care costs. The
second class is the pandrug6-resistant Gram negative bacteria, which

include

Acinobacter baumanni and Pseudomonas aeruginosa. While the numbers of
infections due to these pathogens are smaller than those from Gram positive
microbes, they are more challenging to treat because of their unique cell wall and
the presence of active efflux pumps. The final class of pathogens is the
extensively drug-resistant Mycobacterium tuberculosis. Currently, the treatment for
this pathogen includes a multi-drug regimen which must be given for about six
months. The long treatment period leads to compliance problems which in turn
leads to more resistant mycobacterium.7
The rise of antibiotic-resistant infections has placed pressure to develop
new antibiotics. Historically, novel antibiotics have come from elaboration and
modification

of

existing

antibiotic

scaffolds.

These

scaffolds

(pencillins,

cephalosporins, quinolones, macrolides and tetracyclines), discovered between
the 1940 and 1960s, have formed the basis for most currently used antibiotics.This
approach has been successful and has contributed to the large commercial market
for antibiotics. For example, the early modifications of penicillin resulted in
significantly better compounds with greater spectrum, potency, resistance to β-

3

lactamases, and better pharmacokinetics. Ampicillin, with an expanded spectrum
and methicillin, with increased resistance to β-lactamases are successful
examples of this approach. While making incremental changes on existing drugs
may be a good short-term strategy, there is clearly a need to discover novel
antibiotics with new mechanisms of action.
Unfortunately, despite the increase in infections due to resistant pathogens,
the rate of new drugs entering the market is very low.7,

8

Since 1995 only three

new classes of antibiotics have been introduced. The first class is the
oxazolidinediones (linezolid), which inhibit protein synthesis. The second class is
the lipopeptides, represented by daptomycin, which are believed to act by
inhibiting plasma membrane functions. Finally, the third class of compounds are
mutlins, which exert their action by inhibiting the 50s ribosomal subunit by binding
to an unique binding site.7 What is most worrisome about these new drugs is the
fact that despite their recent introduction to the clinic, resistance to these agents
has already been detected. For example, an Enterococci species resistant to
linezolid was detected in 20039 and a Corynebacterium jeikeium strain resistant to
daptomycin was discovered in 2009.10
One of the more important objectives for future antibiotic drug discovery is
to identify new, validated targets. Attractive targets are gene products that must be
expressed for the survival of the organism. These targets can be broadly
distributed into generic classes such as DNA replication, RNA synthesis, protein
biosynthesis, cell integrity, aromatic amino acid biosynthesis, cell division, two

4

component

signal

biosynthesis.11-14

transduction,

These

general

fatty

acid

categories

biosynthesis,
have

been

and

isopreniod

validated,

since

commercially available antibiotics exist for each.11-14 One unexplored pathway for
antimicrobial drug design is de novo purine biosynthesis. As revealed in studies
conducted in the 1980s, bacteria, yeast, and fungi synthesize the purine
intermediate inosine monophosphate (IMP) via 11 enzymatic steps, whereas in
humans, only 10 steps are required (Figure 1). The differences in pathways
between microbes and humans indicate that purine biosynthesis may be an ideal
target for antibiotic drug discovery.
1.2.

Purine biosynthetic pathway:
The purines, adenine and guanine, are essential chemical components

utilized in various biochemical reactions in the cell. For example, these nucleotides
are used for both DNA and RNA synthesis and they are used as precursors to
second messengers in the cell. These nucleotides are essential carriers of
chemical energy and they are components of the cofactors NAD, FAD, Sadenosylmethionine, and coenzyme A.
Given the importance of the purines, there are two pathways for their
synthesis. The first, called the salvage pathway, prepares new purine nucleotides
by recycling existing purine bases. The second pathway, de novo purine
biosynthesis, prepares purine metabolites from non-purine precursors. This
pathway is necessary for the cell division and is required for rapidly dividing
cells.15, 16
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1.2.1. Salvage pathway16:
Free purine bases are constantly released in cells during the metabolic
degradation of nucleotides. To utilize these bases, the salvage pathway converts
them into the corresponding nucleotide. One of the primary salvage pathways
consists of a single reaction catalyzed by adenosine phosphoribosyltransferase, in
which free adenine reacts with phosphoribosyl pyrophosphate (PRPP) to yield the
corresponding adenine nucleotide. Free guanine and hypoxanthine (the
deamination product of adenine) are salvaged in a similar fashion by the activity of
the enzyme guanine phosphoribosyltransferase.
The amount of nucleotides produced from the salvage pathway is quite low,
roughly 1% or less of the amount required for synthesizing the cell’s DNA.
Therefore, cells must continue to synthesize nucleotides by the de novo purine
biosynthetic pathway so that nucleic acids can be synthesized.15, 16
1.2.2. The “classical” de novo purine biosynthetic pathway15, 17:
De novo purine biosynthesis was elucidated in the 1950s by Buchanan and
co-workers.15 They determined that the pathway contained 10 enzymatic steps
which converted PRPP into Inosine monophosphate (IMP). The pathway was
believed to be universal in all organisms.15
In de novo purine biosynthesis PRPP provides the foundation on which the
bases are constructed step by step (Figure 1).1

1

The naming of the purine biosynthetic enzymes and intermediates can be confusing. To aid the reader,
tables 1 and 2 contain a complete list of acronyms of the purine biosynthetic enzymes, intermediates and
abbreviations for those intermediates.
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Figure 1. De novo purine biosynthetic pathway
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Table 1. List of abbreviations utilized for purine biosynthetic pathway
intermediates.
Abbreviation of Expanded name
intermediate
PRPP
5-Phosphoribosylpyrophosphate
PRA

5-Phospho-D-ribosylamine

GAR

Glycinamide ribonucleotide

FGAR

N-Formylglycinamide ribonucleotide

FGAM

N-Formylglycinamidine ribonucleotide

AIR

Aminoimidazole ribonucleotide

N5-CAIR

N5-Carboxyaminoimidazole ribonucleotide

CAIR

Carboxyaminoimidazole ribonucleotide

SAICAR

Succino 5-aminoimidazole-4-carboxamide ribonucleotide

AICAR

Aminoimidazole-4-carboxamide ribonucleotide

FAICAR

5-Formamido-4-imidazolecarboxamide ribonucleotide

IMP

Inosine monophosphate
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Table 2. Enzymes of Purine biosynthetic pathway:
Gene name

Enzyme name

PurF

Amidophosphoribosyltransferase

PurD

Glycinamide ribonucleotide (GAR) synthetase

PurN

Glycinamide ribonucleotide (GAR) transformylase

PurT
(prokaryotic)

Formylglycinamide ribonucleotide(FGAR) synthetase

PurL

Formylglycinamidine ribonucleotide (FGAR) synthetase

PurM

Aminoimidazole ribonucleotide (AIR) synthetase

PurE (Class II)

Aminoimidazole ribonucleotide (AIR) carboxylase

PurK
(prokaryotic)

N5-Carboxyaminoimidazole ribonucleotide (N5-CAIR) synthetase

PurE (Class I)
(prokaryotic)

N5-Carboxyaminoimidazole ribonucleotide (N5-CAIR) mutase

PurC

N-Succinyl-5-aminoimidazolyl-4-carboxamide
(SAICAR) synthetase

PurB

SAICAR lyase

PurH

5-Aminoimidazole-4-carboxamide
transformylase

PurP
(prokaryotic)

Flavin 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)
synthetase

PurJ

Inosine monophosphate (IMP) cyclohydrolase

PurO
(prokaryotic)

Inosine monophosphate (IMP) cyclohydrolase

ribonucleotide

ribonucleotide

(AICAR)
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The first step, which is the committed step, is the displacement of
pyrophosphate from PRPP by ammonia to produce 5-phosphoribosylamine (PRA).
Amidophosphoribosyltransferase (PurF) catalyzes this reaction. In the second
step, glycine is coupled to the amine group of PRA to produce glycinamide
ribonucleotide (GAR). GAR synthetase (PurD) catalyzes this reaction. The next
reaction is the transfer of a formyl group from N10-formyltetrahydrofolate to the
amino group of GAR to form N10-formyl glycinamide ribonucleotide (FGAR). This
step is catalyzed by GAR transformylase (PurN). In the fourth step, the enzyme
formylglycinamidine synthetase converts FGAR to FGAM. Aminoimidazole
ribonucleotide (AIR) is synthesized in the fifth step by the action of the enzyme
aminoimidazole ribonucleotide synthetase (PurM).

This step results in the

synthesis of the first heterocycle of the pathway. AIR and CO2 are directly
converted to CAIR by the enzyme AIR carboxylase.
In the seventh step, the carboxyl group of CAIR is phosphorylated and the
phosphate is displaced by the amino group of aspartate to produce
succinylaminoimidazole carboxamide ribonucleotide (SAICAR). This step is
catalyzed by SAICAR synthetase (PurC). In the eighth step, fumarate, an
intermediate in the citric acid cycle, is eliminated from SAICAR to yield
aminoimidazole 4-carboxamide ribonucleotide (AICAR). This step is catalyzed by
SAICAR lyase.

AICAR is converted to formamidoimidazole carboxamide

ribonucleotide(FAICAR) with the help of N10-formyltetrahydrofolate and AICAR

10

transformylase (PurH). The final intermediate cyclizes with the loss of water by a
cyclohydrolase to form IMP18.
1.2.2.1.

Divergence in de novo purine biosynthesis:

The only carbon-carbon bond forming reaction in de novo purine
biosynthesis occurs in the sixth step (Figures 1, 2).

In this reaction, AIR

carboxylase catalyzes the conversion of AIR to CAIR. Studies of the step in
bacteria, yeast and fungi were initiated by attempting to identify the AIR
carboxylase gene in these microbes. In these single-cell organisms, the gene is
encoded by the PurE locus. In the late 1980s, genomic sequence analysis
experiments conducted by Zengado et al. and Watanabe et al. identified two
distinct genes within this locus and they termed these PurE and PurK.19 In seminal
experiments conducted by Zalkin using chicken liver cDNA, he found a 429 amino
acid protein that corresponded to PurE locus.19, 20 This protein appeared to have
functions similar to bacterial PurE-PurC, yet surprisingly, no enzyme with a PurKlike sequence was identified. This suggested that the chicken AIR carboxylase
was similar to the bacterial PurE protein, yet there appeared to be no PurK protein.
Thus, at the completion of these studies, an unanswered question remained
regarding the role of PurK in the sixth step of the pathway.20
To address this question, both PurK and PurE gene products from bacteria
were purified to homogeneity and their physical and catalytic properties were
thoroughly studied by Firestine et al. and Mueller et al.19-23 These groups observed
that homogeneous PurE was capable of catalyzing the carboxylation of AIR to
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CAIR; however, a high non-physiological concentration of HCO3- was required
(0.18 M) to observe a reaction. Initial studies on PurK revealed that it had the
ability to catalyze the hydrolysis of ATP to ADP and Pi. This ATPase activity,
however, only occurred in the presence of AIR. Experiments designed to look for
the production of CAIR concomitant with this AIR-dependent ATP hydrolysis were
all negative. Experiments in which both proteins were included revealed the
conversion of AIR to CAIR in the presence of “low” concentrations of HCO3- (100
µM), but only in the presence of ATP. Furthermore, every molecule of AIR
consumed is accompanied by production of an equivalent amount of ADP and Pi
were produced.23 These studies revealed that both PurE and PurK appeared to be
involved in the conversion of AIR to CAIR. PurE appeared to be the catalytic
subunit based upon sequence alignments with AIR carboxylase from other
organisms. The function of PurK was unknown, but was believed to be involved in
the utilization of bicarbonate.19, 20
To explain the function of PurK, the Stubbe lab23 took advantage of the
work done by Alenin et al on the chemistry of AIR.24 Alenin et al found that
incubation of AIR with sub molar concentrations of bicarbonate lead to the nonenzymatic production of a new species. Subsequent studies indicated the new
compound to be the N5-carbamate, which was named as N5-CAIR (Scheme 1).23
Scheme 1. Non enzymatic production of N5-CAIR
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These studies revealed that at higher concentrations of bicarbonate, AIR is
converted into N5-CAIR, and this result suggested that N5-CAIR might be the true
substrate for PurE. Additional studies including NMR spectroscopy and kinetic
analysis showed that this was the case.23
What is the function of PurK? Stubbe et al. hypothesized that the role of
PurK was to produce N5-CAIR under low bicarbonate conditions. Subsequent
NMR spectroscopic and kinetic analysis confirmed this hypothesis (Scheme 2). An
investigation of the mechanism of the reaction by positional isotope studies
suggested that the reaction proceeded via the formation of carboxyphosphate.
Whether carboxyphosphate dissociated to give carbon dioxide, which is then
attacked by AIR to form N5-CAIR or whether carboxyphosphate is directly attacked
by AIR was unsolved at the time.23
Scheme 2. Proposed hypothesis for PurK and PurE biochemistry in eukaryotes
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Figure 2. Divergence in purine biosynthetic pathway
The observed biochemical divergence in the pathway is echoed in the
genetic and protein organization of the pathway. In higher eukaryotes, the de novo
pathway uses a variety of multifunctional proteins in which multiple enzymatic
activities are included within the same polypeptide. For example, steps 2, 3 and 5
are catalyzed by a trifunctional protein, while steps 6 and 7 are catalyzed by a
bifunctional protein. Other multifunctional proteins are involved for other steps in
the pathway. However, there exist at least three monofunctional enzymes
(glutamine

PRPP

amidotransferase

(PurF)

(step

1),

Flavin

GAR

amidotransferase(PurL) (step 4) and SAICAR lyase (PurH) (step 8)) that are
needed as well. The fusion of multiple enzymes into one polypeptide chain has
suggested that substrate channeling could be important; however, repeated efforts
to identify channeling have failed. Recently work from the Benkovic lab
demonstrated that a large, multiprotein complex called the purinosome forms

14

under low purine conditions.25 This complex requires the presence of other cellular
proteins which provides some rationale for why complexes were not previously
observed. Lower eukaryotes have some multifunctional proteins, but not as many
as seen in higher eukaryotes.

In prokaryotes, such as Escherichia coli,

monofunctional enzymes are found throughout this pathway, with the sole
exception

for

the

bifunctional

enzyme

which

ends

the

pathway

(aminoimidazolecarboxamide ribonucleotide transformylase (PurP) (step 10) and
IMP cyclohydrolase (PurO) (step 11)).
1.2.3. Structure and function similarities among purine biosynthetic enzymes:
The crystallographic structures of all known purine biosynthetic enzymes
have been solved 17. The availability of these structures gives us the opportunity to
study the structure-function similarities between the enzymes, and these
relationships have important implications for the evolution of the proteins and the
pathway.
1.2.3.1.

Class I and Class II PurEs:

Class I and Class II PurEs represent an example of structurally and
functionally similar enzymes in purine biosynthetic pathway. Class II enzymes
catalyze the direct carboxylation of AIR to form CAIR, while class I enzymes
require N5-CAIR, which is the product of PurK. Even though both of these
enzymes are evolutionarily related, they are specific for their substrates.17, 26
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1.2.3.2.

ATP-grasp superfamily enzymes in purine biosynthesis:

There are four ATP-grasp superfamily enzymes in the purine biosynthetic
pathway. These are PurD, PurT, PurK, and PurP. There are three other enzymes,
PurL, PurM, and PurC in the purine biosynthetic pathway that utilize ATP, but do
not belongs to the ATP-grasp superfamily of enzymes. ATP-grasp enzymes are
characterized by a unique three domain structure and the name of the superfamily
is derived from the specific arrangement of domains needed to bind ATP. The
three domains are usually called the A, B, and C domains. The A and B domains
constitute the core of the protein and provide the binding sites for the substrates.
The ATP binding site is located in the B domain. The phosphate chain of ATP is
firmly anchored into a well-defined pocket created by the P-loop in the B domain.
The P-loop is thought to provide critical residues needed for the stabilization of the
intermediates during catalysis. All four purine enzymes share a highly homologous
three-dimensional

structure

and

are

believed

to

proceed

through

a

carboxyphosphate intermediate or acylphosphate intermediate to catalyze the
reaction between the carboxylate and the amine as shown in Scheme 3. These
similarities are also found in other enzymes that are not part of purine
biosynthesis. For example, biotin carboxylase, D-alanine-D-alanine ligase, and
carbamoyl phosphate synthetase all belong to the ATP-grasp superfamily. All of
these enzymes proceed through similar reaction mechanisms as outlined in
Scheme 4.17, 23
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Scheme 3. The proposed acylphosphate and carboxyphosphate intermediates in
the reactions catalyzed by PurD, PurK, PurT, and PurP. The amide group formed
in each reaction is indicated in red color.

1.2.4. Genetic studies support de novo purine biosynthesis as an antimicrobial
target:
The purine and pyrimidine biosynthetic pathways of an organism have been
shown to be linked to its virulence within the host.27,

28

In fact, one antifungal

agent, flucytosine, has already exploited the unique enzymes in the pyrimidine
pathway of Candida and Cryptococcus spp. to inhibit effectively the growth of
these yeasts in vivo.29 An association between decreased virulence and purine
auxotrophy in bacteria and fungi is also well documented. As early as 1950, Bacon
et al. reported that Salmonella strains carrying a mutation in the purine
biosynthetic pathway were markedly less virulent than the wild-type strain in
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mice.30 The decrease in the virulence of purine auxotrophs has also been found in
Salmonella typhimurium27, Salmonella dublin27, Klebsiella pneumoniae31, Bacillus
anthracis32, Yersinia pestis33, and Candida albicans.28,

34

The association of

decreased virulence and purine auxotrophy presumably results from the inability of
the organism to multiply sufficiently in the host environment, reflecting the limited
availability of nutrients or the inability to use exogenous metabolites from the
host.35 In a study carried out by Perfect et al., the importance of an intact purine
metabolic pathway in C. neoformans was examined using a meningitis animal
model.29 The inactivation of the phosphoribosylaminoimidazole carboxylase gene
(Class II PurE or ADE2) in C. neoformans by mutagenesis and subsequent
restoration by transformation were used to correlate directly the functional activity
of this gene with the yeast's ability to grow within the subarachnoid space.29 They
found that the C. neoformans ade2 auxotroph was not able to replicate, while
complemented C. neoformans ade2 restored the virulence and growth of the
organism.29 In an interesting study aimed at identifying the virulence factors in
Streptococcus pneumonia, various purine enzymes including PurE, PurK, PurC,
and PurL were identified as the virlulence genes.36
Genetic studies conducted by Donovan et al. also confirmed that the ADE2
gene and de novo purine biosynthesis were required for Candida pathogenicity.37
In this study, the virulence of a ade2- C. albicans strain was evaluated in an
immunosuppressed model of systemic candidiasis. The ade2- strain was unable to
proliferate in the kidney and was nonpathogenic compared to its parent strain. The
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reduced virulence of the strain resulted directly from the block in de novo purine
biosynthesis and the inability of the organism to scavenge purines from the host.
Further, they identified that only a single copy of the ADE2 gene was required to
restore wild-type virulence.37
Analysis of virulence and inflammatory potential of Shigella flexneri purine
biosynthesis mutants revealed that PurE and PurK genes are necessary for the
virulence in animal models of shigellosis.38 In their experiments, Cersini et al,
constructed S. flexneri mutants of PurE and PurK. These mutant were shown to
have no virulence, and the bacterial growth of these strains was very low in
contrast to the unmodified strains of S. flexneri.38
In summary, PurK (N5-CAIR synthetase) is a purine biosynthetic enzyme
that is unique to bacteria, yeast and fungi. Humans do not have this enzyme and
have no homologs of this enzyme. Various genetic and biochemical studies have
proved that PurK gene is a virulence factor.28, 29, 36-39
These studies indicate that N5-CAIR synthetase is a validated target for the
development of novel antibiotics. In this thesis, I will present biochemistry,
enzymology, and medicinal chemistry studies on N5-CAIR synthetase with the
goal of understanding the mechanism of the enzyme and the identification of
inhibitors of the enzyme.
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Chapter 2.
RESULTS
2.1.1. Site-directed
directed mutagenesis on the AIR binding site
site:
The crystal structures of N5-CAIR synthetase from Aspergillus clavatus and
E. coli with various substrates bound were obtained in collaboration with Professor
Hazel Holden of the University of Wisconsin, Madison. Structural studies on N5CAIR synthetase, as well as solution phase experiments, indicate that the enzyme
exists as a dimer (Figure
ure 3).40-42 Each subunit of the dimer folds into three
domains that are referred to as the A, B, and C domains. Domain A extends from
Met1 to Ala119. Domain B is defined as the region from Glu120 to Trp183, while
domain C is composed of amino acids from Ala184 to Arg
Arg382 (Figure
ure 4). The A
and C domains contribute to the subunit
subunit-subunit
subunit interface, while the B domain is
oriented away from the main body of the molecule
molecule.42

Figure 3.. Crystal structure of the N5-CAIR41synthetase dimer from
Aspergillus clavatus (PDB number: 3K5I). The two monomers of N5-CAIR
synthetase dimer are shown in green and orange colors
colors, respectively.
Bound ADP and AIR ligands are shown in stick representation with blue
color carbon atoms.
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Figure 4. N5-CAIR synthetase monomer from Aspergillus clavatus. Domain
A is shown in green, domain B is shown in yellow, and domain C is shown
in blue. Stick representations of AIR and ATP are shown in their respective
binding sites.

2.1.1. A. ATP binding site:
All of the residues responsible for binding ATP are contributed by the B and
C domains (Figure 5).41 There are two magnesium ions and both are octahedrally
coordinated. One of the magnesium ions is surrounded by Glu254, Glu267, and
the α- and ɣ-phosphoryl oxygens. The other magnesium ion is coordinated by
Glu267, and the β- and ɣ-phosphoryl oxygens of ATP. Glu267 also serves to
bridge the two ions. The binding site contains two positively charged amino acids,
Lys104 and Lys146, which neutralize the negatively charged phosphoryl groups of
ATP. The adenine ring is bound by hydrogen bonds with Lys146 and Glu181, and
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with the carbonyl oxygen of Lys182 and the backbone amide nitrogen of Ala184.
The 2’ and 3’ hydroxyl groups hydrogen bond to the carboxylate of Glu189. The
phenyl ring of Phe183 forms a T-shaped stacking interaction with the adenine
ring.41

Figure 5. ATP binding site of N5-CAIR synthetase. The green spheres
represent the Mg ions.Glu267 and Glu181 and the P-loop coordinate with
the phosphate side chain of ATP. Glu189 hydrogen bonds to the ribose
hydroxyl groups. Phe183 makes a T shaped π-π interactions with adenine
moiety of ATP.

2.1.1. B. AIR binding site (Figure 6):
The crystal structure of N5-CAIR synthetase complexed with Mg:ADP and
AIR is also a dimer. The two ligands are separated by 8 Å. The 5-aminoimidazole
heterocycle of AIR is hydrogen bonded to the carboxylate of Asp153. Glu73 forms
a hydrogen bond to the 2’ and 3’ hydroxyl groups of the ribose, whereas the
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positively charged side chains of Arg155, Lys345, and Arg352 participate in
electrostatic interactions with the 5’ phosphate of AIR. An additional hydrogen
bond is formed between Tyr152 and the phosphoryl oxygen of the AIR. Tyr152
also forms a stacking interaction with the aromatic imidazole ring of the substrate.
Lys353 and Arg271, which are present within the active site, do not appear to
interact directly with AIR. Rather, Lys353 hydrogen bonds to Asp153 and
presumably stabilizes the conformation of the aspartic acid. The function of
Arg271 is unknown; however, given its location, it is reasonable to speculate that
Arg271 may play a role in bicarbonate binding and utilization.
The availability of the Mg:ADP:AIR structure provided us with the necessary
information to begin to assess the function of amino acids located in the AIR
binding site. Given the structural information, the investigations reported here
focused on five residues (Glu73, Tyr152, Asp153, Arg155, and Lys353) for sitedirected mutagenesis and analysis. Although Lys353 does not appear to directly
contact AIR, we choose to investigate this residue because of its close proximity to
Asp153. Each residue was mutated to alanine, and the resulting proteins were
purified as His6-tagged proteins using a metal chelate column. The resulting
purified proteins were judged to be at least 95% pure by gel electrophoresis. To
investigate the role of each residue in AIR binding, each mutated protein was
analyzed by steady-state kinetics and equilibrium dialysis.41
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Figure 6. AIR binding site. Top: Close
Close-up
up view of the AIR binding site from
Aspergillus.. The protein is shown in ribbon form and AIR is depicted in stick
representation. Critical residues (see bottom portion of figure) are also
shown in stick representation. Bottom: Detailed model of the AIR binding
site. Asp153 interacts with the N5 of AIR via hydrogen bonding. The
hydroxyl group of tyrosine hydrogen bonds to the phosphoryl oxygen of AIR
while the phenyl ring forms an aromatic stacking interaction with the
imidazole ring of AIR. Glu73 interacts with the 2’ and 3’ hydroxyl groups of
ribose. Arg352
rg352 and Arg155 neutralize the negative charge of the phosphate
of AIR.
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2.1.1. C. Kinetic and thermodynamic characterization of site-directed mutants:
Kinetic characterization of the site-directed mutants was accomplished
using the previously reported ADP-coupled pyruvate kinase and lactate
dehydrogenase assay (Figure 7).43 The initial velocity versus substrate
concentration was fitted to the Michelis-Menten equation using Kaleidagraph to
determine the kinetic parameters Vmax and Km. The catalytic turnover

of the

enzyme, kcat, was determined from the equation kcat = Vmax/[E].18 The molecular
weight of the dimer (89,486 daltons) was used for calculating the enzyme
concentration.
It is well known that Km cannot be used as an accurate determination of the
dissociation constant (Kd) for substrate binding, since Km depends up on multiple
rate constants. To determine Kd, we used equilibrium dialysis. This experiment
was done by placing the enzyme (10-12 µM) inside a dialysis bag and individual
bags were dialysed against six different concentrations of AIR ranging from 1 to
300 µM. The bound AIR was determined spectrophotometrically from the
absorbance of the solution at 250 nm (ε 3,270 M-1 cm-1). The concentration of AIR
bound was plotted against the total amount of AIR added and the Kd was
determined by fitting the data to the quadratic equation (Table 3 and Equation 1).




 




  

 

(1)

For Equation 1, ET is the total enzyme concentration, AIRT is the total AIR
concentration, AIRbound is the amount of AIR bound to the enzyme, and Kd is the
dissociation constant.
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Figure 7. The coupled N5-CAIR synthetase assay
Table 3. Kinetic and thermodynamic parametersa determined for site-directed
mutants.
Kmb
Kdc
kcatd
kcat/Km
Vmaxb
Mutant
(µM. min-1. mg-1) (µM)
(µM)
(min-1)
(µM-1. min-1)

a

Wild type 50±3

25±5

20±8

4140±250 330±70

D 153A

0.03±0.001

40±7

20±3

2.50±0.05 0.12±0.02

R 155A

6±0.5

180±40

1.6±0.5 510±40

Y 152A

1±0.2

460±120 50±20

110±20

0.50±0.2

E 73A

0.03±0.003

140±40

9±4

2.5±0.3

0.04±0.01

K 353A

inactivee

NA

20±5

NA

NA

6.0±1

b

Reported errors are those obtained from curve fitting the appropriate data set. Steady-state
values were determined using the ATP-coupled assay system with the concentration of ATP and
c
bicarbonate fixed and the concentration of AIR varied. Calculated from equilibrium dialysis
d
experiments using eq 1. Calculated using the molecular weight of the dimer. Calculations were
e
conducted assuming that 100% of the protein was active. No measurable activity up to a protein
concentration of 725 µg/mL.

A comparison of the kinetic parameters for the wild-type enzyme versus the
mutated enzymes revealed that all of the mutations decreased the catalytic
proficiency of the enzyme by 50-8,000 fold (Table 3). The Km of AIR for the mutant
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proteins increased, yet surprisingly, for most, the Kd of AIR remained either
unchanged or decreased. We expected that mutations in the substrate binding site
would weaken the binding of AIR.
Mutation of Tyr152 resulted in a significant increase in Km and only a
moderate increase in Kd. This residue is of particular interest given the recent
discovery that substitution of a tyrosine at this location in the E. coli PurT-encoded
glycinamide transformylase confers N5-CAIR synthetase activity to the enzyme44.
As mentioned above, Tyr152 forms a hydrogen bond to the phosphate group of
AIR and also has stacking interactions with the imidazole ring of the substrate.
These interactions might be responsible for locking AIR into a specific
conformation. We believe that in the absence of the Tyr152, AIR adopts a different
conformation that is non-productive, thus resulting in the drastic decrease in
enzyme proficiency (kcat/KM) observed in this mutant.
The Glu 73A mutant displayed a 1,400 fold decrease in catalytic efficiency,
yet structural information indicates that this residue is distal to the site for catalysis.
We are uncertain why Glu73 has such a profound effect on catalysis. One possible
explanation is that this residue is important in optimizing the alignment of AIR into
the active site. Mutation to this residue did not directly alter the affinity of AIR
binding, but instead may alter the alignment of AIR for nucleophilic attack.
One critical question regarding the mechanism of N5-CAIR synthetase is
the identity of the active site base that removes the proton from the exocyclic
amine of AIR. Analysis of the crystal structures of the enzyme reveal that Lys 353
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is ∼4 Å from the exocyclic amine of AIR, whereas Asp153 is only 3 Å distant.
Replacement of Asp153 with alanine results in an enzyme with essentially the
same Km and Kd as the wild-type enzyme, but with a kcat value more than 1,600fold lower. Clearly, Asp153 is involved in catalysis, but not substrate binding.
Mutation of Lys 353 to alanine generated an inactive enzyme. The mutant protein,
however, was capable of binding AIR with the same affinity as the wild-type
enzyme. On the basis of our structural information, we suggest that Lys 353 is too
distant to function as the catalytic base and likely plays another role in catalysis.
However, we realize that the existing kinetic information cannot definitively rule out
Lys353 as the catalytic base.
2.1.1. D. Bicarbonate-dependent ATPase activity of the enzyme:
To determine whether N5-CAIR synthetase can catalyze the half reaction
(that is attack by bicarbonate onto ATP to generate carboxyphosphate), we
determined the rate of ATP consumption in the presence of added bicarbonate,
but in the absence of AIR. We measured ATP consumption via the pyruvate
kinase and lactate dehydrogenase system. Incubation of 28 µg of enzyme with
various concentrations of bicarbonate generated a dose-dependent increase in
ATP consumption as shown Figure 8. This data indicates that N5-CAIR synthetase
is capable of catalyzing the attack of ATP by bicarbonate. This half-reaction has
also been observed for other ATP-grasp carboxylation enzymes.45 The data were
fitted to the Michelis-Menten equation to generate a Km app of 3.2mM and Vmax of
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0.09 µmol/min.mg. The Vmax for the half reaction is 800 times lower than for the full
reaction (Vmax for full reaction is 73 µmol/min.mg).

Figure 8. Bicarbonate dependent ATPase activity of N5-CAIR synthetase.
The ability of the enzyme to catalyze the attack of ATP by bicarbonate in
the absence of AIR was measured using the coupled assay shown in figure
7. The curve shown in the fit of the data to the Michelis-Menton equation.

2.1.2. Modeling carboxyphosphate into the active site of N5-CAIR synthetase:
N5-CAIR synthetase in the presence of AIR, ATP, and [18O]-bicarbonate
catalyzes quantitative transfer of
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O from bicarbonate to inorganic phosphate.23

N5-CAIR synthetase also shows bicarbonate-dependent ATPase activity. These
observations suggest that bicarbonate reacts with ATP to generate the highly
reactive

intermediate

carboxyphosphate.23

Carboxyphosphate

has

been

implicated in the mechanism of other ATP-grasp enzymes including biotin
carboxylase and carbamoyl phosphate synthetase.42,

46-50

Carboxyphosphate,

unfortunately, is highly unstable and has a predicted half life of 70 milliseconds.23
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Indeed, direct experimental evidence for this intermediate has only been
determined once for one enzyme.51
Since carboxyphosphate is critical to the mechanism of the enzyme, it
would be of great utility to have the structure of this intermediate bound to the
enzyme.

Carboxyphosphate, however, is very unstable and is a transient

intermediate in the reaction. Thus, a crystal structure of this intermediate bound to
the enzyme is not possible. To circumvent this problem, we sought to generate a
molecular model of carboxyphosphate bound to the enzyme from the available
crystal structures.
2. 1. 2. A. Computational studies on carboxyphosphate:
The use of bicarbonate as a nucleophile in phosphoryl transfer reactions
was extensively investigated by Herschlag et al.52-54 These studies revealed that
phosphoryl transfer proceeds with the aid of an intramolecular hydrogen bond.
This hydrogen bond seems to orient the negatively charged oxygens of
bicarbonate away from the negatively charged phosphate group. The reaction and
the proposed transition state is shown in Figure 9.52

Figure 9. Phosphoryl transfer onto bicarbonate. In this reaction, pyridine
phosphate is attacked by bicarbonate. Physical chemistry studies on this
reaction reveal that the reaction proceeds via an intramolecular hydrogen
bond.
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Using this information, we modeled carboxyphosphate in both the pseudo-chair
and extended conformations and subjected each conformation to quantum
mechanical calculations (as executed by Gaussian) to determine the most stable
conformation.41,

55

The computational studies revealed that the pseudo-chair

conformation is 13 kcal/mole more stable than the extended conformation (Figure
10). Given this and the physical chemistry studies by Herschlag and colleagues, it
is logical to assume that during catalysis by N5-CAIR synthetase, the pseudo-chair
conformation

of

carboxyphosphate

is

also

formed.40

The

pseudo-chair

conformation in part stabilized by a hydrogen bond between the proton on the acid
and one of the oxygens on the phosphate. In this arrangement, it is possible for
the phosphate group in carboxyphosphate to act as a base to remove the proton.
Such an intramolcular proton has been observed in the decomposition of
carbamoyl phosphate.56 To determine the relative enegy difference between two
pseudo-chair structures, we conducted quantum mechanical calculations. These
calculations reveal that carboxyphosphate with the proton on the phosphate is
more stable by 4.8 kcal/mole. The result of these two calculations suggested that
carboxyphosphate adopts a conformation that allows rapid, non-enzyme mediated
transfer of the proton from bicarbonate onto phosphate.
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Figure 10. Top:Computational studies on the conformations of
carboxyphosphate. Quantum mechanical calculations (Gaussian, B-3LYPG* basis set) showed that the pseudo-chair conformation is more stable
than the extended conformation.
Bottom: Semi-empirical calculations on the conformation and hydrogen
transfer of carboxyphosphate.
2.1.2. B. Modeling of carboxyphosphate in the N5-CAIR synthetase active site:
In order to model the pseudo-chair conformation of carboxyphosphate into
the active site of N5-CAIR synthetase, we need to know the location of the
carboxyphosphate binding site. To identify this site, we took advantage of the N5CAIR synthetase:ADP:Pi:Mg crystal structure (Figure 11, PDB: 3ETJ). This
structure was obtained when crystals of E. coli N5-CAIR synthetase were
incubated with AIR and ATP.40 The formation of ADP and Pi indicates that the
enzyme is active in the crystal. This, in turn, suggests that the location of the
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inorganic phosphate represents the site of carboxyphosphate binding since this
phosphate group must come from this highly unstable intermediate. Superposition
of the phosphate group of the pseudo
pseudo-chair
chair carboxyphosphate model with
w
the
phosphate of the crystal structure should provide a logical model for this
intermediate bound to the enzyme. The resulting model can be found in Figures 12
and 13.

Figure 11. ADP and Pi binding site of E. coli N5-CAIR
CAIR synthetase. The
protein is shown as a grey ribbon
ribbon, while the location of ADP and Pi is
shown in stick representation with green carbon, orange phosphorous, blue
nitrogen and red oxygen atoms. Mg2+ atoms are shown as light green
spheres.
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Figure 12. The model of the active site of Aspergillus N5-CAIR
CAIR synthetase
with ADP, AIR, and carboxyphosphate bound. Carboxyphosphate was
modeled onto the location of Pi determined from the crystal structure of E.
coli N5-CAIR
CAIR synthetase (PDB: 3ETJ)
3ETJ).41 The location of ADP and AIR are
experimentally determined (PDB: 3K5I).41 The protein is shown as a grey
ribbon with the molecules show
shown
n in stick representation with green carbon,
orange phosphorous, blue nitrogen
nitrogen, and red oxygen atoms.
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Figure 13. (left). Close
Close-up view of Aspergillus clavatus N5-CAIR
CAIR synthetase
active site with carboxyphosphate modeled into the site. The picture shows
the carbonyl oxygen atoms of carboxyphosphate are nicely placed between
Arg271 and Lys353. The representations within the figure are the same as
those found in Figure 10. (Right) The carbondioxide produced upon
dissociation of carboxyphosphate is shown in the model.

An examination of the model ((Figure 13) reveals that the two carbonyl
oxygen atoms of carboxyphosphate are beautifully placed between Arg271 and
Lys353. Thus, it is logical to conclude that these residues could aid in the
formation or breakdown of this intermediate. Previous researchers have
speculated that carboxyphosphate is the electrophile in other carboxylation
enzymes (i.e. carbamoyl phosphate synthetase)
synthetase).51 However, in our model, the
distance between the exocyclic amine of AIR and the carbonyl carbon of
carboxyphosphate is ~4 Å and the angle of approach is incorrect. This suggests
that AIR does not directly attack carboxyphosphate. Instead, we propose that
carboxyphosphate

decomposes

to

CO2

and

HPO4-.

Decarboxylation

of
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carboxyphosphate may be catalyzed by an intramolecular proton abstraction by
the phosphate group to yield HPO4-. This proposal is based upon computational
studies, which show that the proton in carboxyphosphate prefers to be located on
the phosphoryl group and the fact that HPO4- is the form of phosphate that is
released by another ATP-grasp carboxylation enzyme, biotin carboxylase.23, 52, 57
This reaction could also be aided by both Arg271 and Lys353.
The above hypothesis suggests that N5-CAIR synthetase may have the
ability to bind and stabilize CO2. To investigate this hypothesis, we conducted an
experiment to determine if N5-CAIR synthetase is able to synthesize N5-CAIR in
the absence of ATP. Addition of 112 µg of enzyme to a solution containing AIR
and 20 mM HCO3- resulted in a decreased absorbance at 250 nm due to N5-CAIR
synthesis. Reactions conducted in the absence of the enzyme or in the presence
of BSA instead of N5-CAIR synthetase resulted in no N5-CAIR production (Figure
14). This experiment provides definitive evidence that the enzyme utilize CO2 as a
substrate.
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Figure 14. Synthesis of N5-CAIR by N5-CAIR synthetase in the absence of
ATP. Red: AIR and bicarbonate, no enzyme; Green: AIR, bicarbonate and
BSA instead of N5-CAIR synthetase; Blue: AIR, bicarbonate and N5-CAIR
synthetase.
2.1.3. Proposed mechanism of N5-CAIR synthetase:
Our proposed mechanism is shown in Figure 15. In this mechanism, we
start after the formation of carboxyphosphate. Carboxyphosphate is stabilized by
Arg271 and Lys353, where each residue forms hydrogen and electrostatic bonds
with the oxygen atoms of carboxyphosphate. Carboxyphosphate decomposes to
HPO4-2 and CO2 via intramolecular hydrogen abstraction. The resulting CO2 group
is now positioned between Lys353 and Arg271. These residues, which likely are
positively charged, should enhance the electrophilicity of CO2 by drawing electrons
away from the carbon atom. An examination of the CO2 model indicates that CO2
is ∼2.7 Å away from the amine of AIR and there is optimal alignment for
nucleophilic attack by the exocyclic amine. Catalysis likely occurs in a concerted
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fashion such that the amine of AIR attacks the carbon of CO2 as Asp153 removes
the proton from the amine. The resulting negative charge on the oxygen atom of
the carbamate is stabilized by either Arg271 or Lys353.

Figure 15. Proposed mechanism for N5-CAIR synthetase. AIR and
carboxyphosphate are shown in red. The functional groups of the side
chains of amino acids believed to be involved in the mechanism are shown
along with the residue number.
2.2. Discovery of selective N5-CAIR synthetase inhibitors:
The evidence presented in the introduction indicates that N5-CAIR
synthetase is an important target for the design of antibacterial and antifungal
agents. Unfortunately, at the start of this project, no small molecule inhibitors of
the enzyme were known. To correct this problem, we initiated a high-throughput
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screening (HTS) study on the enzyme. HTS was carried out at the Center for
Chemical Genomics located at the University of Michigan, Ann Arbor. The results
of

assay

development,

HTS

screening,

hit

identification,

and

kinetic

characterization of the hits are presented in the following sections.
2. 2.1. Assay development for high-throughput screening:
The published assay for N5-CAIR synthetase (Figure 7) relies upon the
measurement of ADP using a system in which ADP production is coupled to the
reduction of pyruvate. While this assay is well known, it suffers from the problem
that false hits could be generated due to inhibition of the coupling enzymes rather
than N5-CAIR synthetase. Thus, additional screening would have to be done to
identify the true target of any inhibitor identified in the assay.
To circumvent this problem, we utilized the well-known malachite
green/phosphomolybdate assay to detect the AIR-dependent production of
phosphate by the enzyme. In this assay, the phosphate produced complexes with
molybdate to form a colorless complex, which upon reaction with malachite green
generates a blue color that can be measured at 600 nm (Figure 16). We observed
that this assay worked well for N5-CAIR synthetase, could easily be run in 384-well
plates and is highly reproducible (Z’ score of 0.7).
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Figure 16. Phosphomolybdate and malachite green assay for N5-CAIR
synthetase (top). The assay allows for easy analysis by measurement of
absorbance at 630 nm (bottom).

2. 2. 2. Screening compound libraries:
Using this assay, 48,000 drug-like, commercially available compounds
collected from the Maybridge Hit-Finder library (Maybridge), ChemDiv corporation,
Chembridge corporation and the MS Spectrum library were screened at a single
inhibitor concentration ranging from 5 to 27 µM (depending upon supplier). We
found 212 potential inhibitors (hit rate: 0.44%). Dose–response curves, using the
phosphate assay, were generated for the most potent 107 compounds as
determined from the primary screen. Of these, only 14 displayed a dose–response
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relationship (hit rate: 0.03%). Importantly, none of these 14 was identified as hits in
the PubChem database indicating that our compounds display some measure of
selectivity.
2. 2. 3. Classification of the hits:
The structures of the 14 compounds are shown in Table 4 along with their
IC50 values. The hits identified can be classified into three classes based on
chemical structure. Class I contains compounds with an indenedione core. Class II
compounds contain an isatin core, while class III contains compounds that are
structurally unrelated to any other inhibitor. We determined the Michaelis–Menten
kinetics for five compounds (1, 2, 7, 13, and 14) using the standard N5-CAIR
synthetase assay shown in Figure 7.
2. 2. 3. A. Class I compounds inhibit N5-CAIR synthetase by reacting with AIR:
The Michaelis–Menten plot of 1 and 2 versus AIR concentration revealed a
biphasic relationship in which there was a lag followed by an increase in velocity
as the concentration of AIR increased (Figure 17). Examination of the data
revealed that the breakpoint between the lag versus turnover always occurred
when the concentration of AIR was twice that of the inhibitor. This suggested that
the inhibitor reacts with AIR and once the inhibitor is consumed, additional AIR is
available for turnover by the enzyme. Such a result is odd for two reasons. First, in
these reactions, the substrate and the inhibitor are added at the same time to the
enzyme. Thus, the reaction between the inhibitor and AIR had to occur faster than
the conversion of AIR to N5-CAIR. Thus, the reaction between the inhibitor and
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Table 4. Hits from HTS

No.

a

Compound

IC50

a

Ki

b

type

c

No.

Compound

IC50

a

Ki

b

type

1

2.3

NA

R

8

19

ND

NA

2

5.6

NA

R

9

21.9

ND

NA

3

7.76

NA

R

10

23

ND

NA

4

8.7

ND

NA

11

37

ND

NA

5

17

ND

NA

12

69

ND

NA

6

17.38

ND

NA

13

10

62
e
43

d

7

10.47

29
e
40

NC
NC

14

20

81
e
122

d

C
U

d

NC
NC

b

c

IC50 values determined from dose–response curves using the phosphate assay. Ki values
determined using the ATPase assay with variable amounts of either AIR or ATP at a fixed
concentration of bicarbonate. Values determined by curve fitting data using various models of
c
inhibition. Type of inhibition determined by fitting data to the modified Michaelis–Menten equations
for the presence of different types of inhibitors. Equations that produced the best fit to the data
were used to determine the type of inhibition. Results of these curve fits were validated by
Lineweaver–Burke plots. R: reacts with substrate; NC: noncompetitive; C: competitive; U:
uncompetitive.
d
Obtained using variable concentrations of AIR and fixed ATP and bicarbonate concentrations.
e
Obtained using variable concentrations of ATP and fixed AIR and bicarbonate concentrations.
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AIR had to occur faster than the conversion of AIR to N5-CAIR. Second, the
structures of the class I inhibitors do not display any obvious reactive groups.

Figure 17. Michaelis-Menten plot of N5-CAIR synthetase in the presence
(■) and absence (●) of 1. The initial velocity of the reaction in the presence
or absence of the inhibitor was determined for the first two minutes of the
reaction using the couple assay system. The breakpoint (intersection of the
two red lines) always appears at twice the concentration of AIR.
An answer to this conundrum raised in the previous section can be found in a
retrosynthetic analysis of these inhibitors. Class I compounds are prepared by
reaction of ninhydrine with an amine or an amide. Given this, we hypothesized
that these molecules may be unstable and could decompose to the 1, 2, 3triketoindane (the dehydrated form of ninhydrin) and either the amine or amide
(Scheme 4). If such a reaction occurred, the 1,2,3-triketoindane present in the
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reaction mixture could react with the amine of AIR thereby preventing AIR from
binding to the enzyme.
We examined aqueous solutions of 1 and 2 by TLC and found that the
compounds decomposed to generate ninhydrin. The rate of decomposition was
dependent upon the chemical nature of the compound. Studies on 1 revealed that
this compound completely decomposed to ninhydrin after approximately 30 min
while decomposition of 2 took around 45 min. This decomposition was not
observed in DMSO solutions of the compounds indicating that a proton
(presumably from water) was necessary for the reverse reaction.
Scheme 4. Reaction of class I inhibitors.

To assess the rate of the reaction, we incubated ninhydrin with AIR and
observed a very rapid reaction (≤20 s) as determined by TLC analysis.
Experiments utilizing TLC and UV spectroscopy indicated that the enzyme did not
catalyze a reaction between AIR and ninhydrin. To determine if the reaction
between AIR and ninhydrin was responsible for the kinetics observed for 1 and 2,
we obtained a Michaelis–Menten plot with variable AIR and ninhydrin. Once again,
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we observed the same kinetic results as for 1 and 2; namely, no reaction until the
concentration of AIR exceeded that of ninhydrin. This suggested that ninhydrin
was responsible for the observed inhibition by removing available substrate from
solution. To confirm this, we examined whether DMSO solutions of 1 or 2 were
capable of inhibiting N5-CAIR synthetase. We found that upon addition of these
non-aqueous solutions, neither compound resulted in inhibition of the enzyme.
Thus, our data suggest that compounds belonging to class I are not true inhibitors
of N5-CAIR synthetase, but rather inhibit the reaction by reacting with the
substrate. Given this mechanism of action, class I compounds do not represent
viable lead agents for the development of antimicrobial agents.
2. 2.3.B. Class II compounds are non-competitive inhibitors of N5-CAIR
synthetase:
We determined the Michaelis–Menten kinetics of compound 7 (Figure 18),
which is the most potent member of the class II family of inhibitors. Kinetic analysis
reveals that 7 is non-competitive with both AIR and ATP. N5-CAIR synthetase has
no known allosteric regulators; however, HTS of other enzymes related to N5CAIR synthetase has identified non-competitive inhibitors as well.58 Given the
structural similarity between 7 and the other class II inhibitors, we anticipate that
all compounds belonging to this class will be non-competitive inhibitors of the
enzyme.
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Figure 18. Kinetic characterization of class II inhibitors with various
concentrations of 7 ((●) 0 lM, (■) 5 lM, (▲) 10 lM, and (♦) 25 lM). A.
Constant AIR and varying ATP; B. Constant ATP and varying AIR.

2. 2. 3. C. Investigation of class III compounds
We have identified two compounds that are chemically unrelated to any
other hits identified in the screen. Steady-state kinetics of 13 (Figure 19) indicates
that the compound is competitive with AIR, but uncompetitive with ATP. This result
suggests that the compound binds to the AIR-binding site of the enzyme only after
ATP binds to the enzyme.
Compound 14 is riboflavin. Although this compound is unlikely to be a lead
agent, we conducted kinetic analysis to determine the mechanism of inhibition.
Steady-state kinetic analysis indicates that riboflavin is noncompetitive with both
AIR and ATP as shown in Figure 20.
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Figure 19. Kinetic characterization of compound 13 various concentrations
((●) 0 lM, (■) 5 lM, (▲) 10 lM, and (♦) 25 lM). A. Constant ATP and varying
AIR; B. constant AIR and varying ATP

Figure 20. Kinetic characterization of compound 14 with various
concentrations ((●) 0 lM, (■) 5 lM, (▲) 10 lM, and (♦) 25 lM). A. Constant
ATP and varying AIR; B. constant AIR and varying ATP

2. 2. 3. D. Class II compounds do not inhibit AIR carboxylase or SAICAR
synthetase:
We assayed compounds 7, 13 and 14 against the human bifunctional
enzyme AIR carboxylase:SAICAR synthetase. We found that at a concentration of
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up to 200 µM of 7, 13, or 14, no inhibition of either enzymatic activity was
observed. Incubation of the enzymes with higher concentrations of the 7, 13, or 14
resulted in precipitation of the compounds. These results indicate that these
agents are selective inhibitors of the microbial enzyme.
2. 2. 4. Class II compounds inhibit E. coli growth:
Class II compounds were tested for their ability to inhibit E. coli cell growth
in liquid cultures. We found that compounds 7 and 11 have minimum inhibitory
concentrations of 64 mg/L and 256 mg/L, respectively. Most importantly, inhibition
by either compound can be rescued by the addition of adenine, indicating that
inhibition of bacterial growth is predominantly due to inhibition of purine
biosynthesis.
In conclusion, we have found that class II inhibitors are novel allosteric
inhibitors of N5-CAIR synthetase, they do not inhibit the human enzyme, AIR
carboxylase, and they display antibacterial activity against Gram-negative
bacteria.
2. 2. 5. Design and synthesis of a class II based photoreactive agent:
The promising kinetic and antibacterial properties of the class II agents
prompted us to initiate a study aimed at determining the structure of the
enzyme:inhibitor complex. Such information would be invaluable for future drug
design studies. Unfortunately, our cocrystallization efforts were unsuccessful
because of the poor aqueous solubility of the class II inhibitors. As an alternative,
we sought to identify the binding site of the class II inhibitors by crosslinking
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studies. To accomplish this, we began a study to create a photoreactive
crosslinker analog of 7 with the goal of identifying the binding site of 7 by
proteomic analysis.
Using the structure-activity relationships observed in our HTS hits, we
reasoned that there were two locations on the core chemical structure that could
be modified. The first was the nitrogen atom on the isatin nucleus since a wide
variety of substituents appeared to be tolerated at this location. The second
location was on the phenyl ring of the isatin core. Given the synthetic ease of
preparing N-substituted derivatives, we choose this location. For the photoreactive
moiety we choose to use a diazirine group. Diazirines are extremely stable under
non-UV conditions, yet these groups can be activated by irradiating at 360 nm59-62
UV irradiation converts diazirines into reactive carbenes, which can nonspecifically react with any neighboring amino acids. Diazirines are also small and
offer limited steric hindrance.

Figure 21. (left) Designed class II diazirine based photoreactive
agent.

Based

upon

these

finding,

we

designed

compound

15

as

our

photocrosslinker (Figure 21). The synthesis of this molecule was accomplished
according to Scheme 5.
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Scheme 5. Synthesis of compound 15.

2. 2. 5. A. Kinetic characterization of the photoreactive agent:
We determined whether compound 15 could inhibit N5-CAIR synthetase
using a dose-response curve. The resulting dose-response curve was used to
determine the Ki value according to the equation Ki= (Vmaxapp* [I])/Vmax, where
Vmaxapp is the apparent Vmax obtained from the dose-response curve, Vmax is the
maximal velocity obtained from the uninhibited curve, and [I] is the inhibitor
concentration. Using this analysis, we found that 15 was a non-competitive
inhibitor with a Ki of 90 µM.

Figure 22. Kinetic characterization of 15. (■)0 µM drug and (○) 90µM drug.
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2. 2. 6. Photocrosslinking studies:
Photocrosslinking studies were performed in phosphate buffered saline. N5CAIR synthetase (PurK) was incubated with 450 µM of 15 in the presence and
absence of AIR and ATP. Control experiments conducted with the known inhibitor,
7, were also conducted. A control reaction containing no 15 was also performed.
All the samples were irradiated with UV light using a 100 watt UV lamp, emitting
radiation between 340-370 nm. SDS-PAGE analysis of the reactions is shown in
Figure 22. The data revealed the presence of a 84 kDa band in addition to the
42KDa band expected for N5-CAIR synthetase. The intensity of 84 kDa band was
diminished in the presence of compound 7 (lane 3, Figure 22) indicating that
compound 7 can compete with the photocrosslinker. This suggests that the
crosslinker and 7 bind to the same site.

Figure 23. Photocrosslinking studies of N5-CAIR synthetase with
compound 15. A. Photocrosslinking studies in presence of inhibitor 7, ATP
and AIR; B. Photocrosslinking studies in presence of 15 at 0, 10, 25, 50, 75
and 100µm concentrations. Note: Denaturing gel.
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In another experiment, we incubated N5-CAIR synthetase with compound
15 at concentrations 0, 10, 25, 50, 75 and 100 µM. Analysis of these reactions
reveal that the 84 kDa band increases in intensity with the increase in compound
15 concentration. This result indicates that there is a direct relationship between
the formation of the 84 kDa band and the concentration of 15.
The presence of the 84 kDa band suggested that 15 caused the formation
of stable, covalent dimers of N5-CAIR synthetase. Solution and crystallographic
studies have shown that the synthetase exists as a dimer in solution. The data
suggests that 15 is crosslinking two monomers together. How does this occur?
Compound 15 contains a diazirine, which is a known photoactivable linker.
However, the other end of the molecule is isatin, which is not known to be an
activatable, reactive group. Our data suggests that the isatin region of 15 is
converted to a reactive species during UV irradiation. The resulting reactive group
then covalently modifies the protein generating crosslinked N5-CAIR synthetase.
Given this unexpected behavior, we initiated a study on the photochemical
properties of isatin and its derivatives.
2. 2. 7. Study of photochemical properties of Isatin:
If isatin is converted into a reactive species by UV irradiation, we predicted
that irradiation of 7 would lead to the generation of a time-dependent inactivation
agent for N5-CAIR synthetase. Two experiments were conducted. In the first
experiment, 1 mM of 7 in dimethylformamide (DMF) was incubated with 20 µM of
N5-CAIR synthetase. At various timepoints during the incubation period, the
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amount of remaining enzyme activity was determined by diluting the enzyme and
assaying for N5-CAIR synthetase activity.
In the second experiment, a DMF solution of 7 was irradiated for 2 hours. A 1 mM
solution of the UV-irradiated solution was incubated with N5-CAIR synthetase and
the remaining enzyme activity was assayed over two hours. The percentage of
enzyme activity remaining was plotted against time to determine whether there
was time-dependent enzyme inactivation.

Figure 24. Time-dependent enzyme inactivation
irradiated 7 (red).

by

7 (blue) and UV

As shown in the Figure 23, 7 did result in the loss of approximately 35
percent of the enzyme activity; however, UV-irradiated 7 inhibited 85 percent of
the enzyme. This suggests that UV irradiation changes 7 into a more reactive
species, which modifies the enzyme. To determine if the inactivation was
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reversible or irreversible, we dialyzed the enzyme:7 (both non-UV and UV treated)
samples for 5 hours and then assayed the samples to determine if

N5-CAIR

synthetase activity was recovered. We observed that for the non-UV irradiated
7:enzyme sample, completely activity was recovered after dialysis; however, for
the UV-irradiated 7:enzyme sample, no activity was restored upon dialysis.
2. 2. 8. HPLC and GC/MS analysis of UV irradiated isatin and understanding the
isatin photochemistry:
To identify the chemical change that is taking place upon UV irradiation, we
conducted a GC/MS study on N-methyl isatin. We choose to use N-methyl isatin
for this studies since the compound is simpler and cheaper than 7 and is readily
available. N-methyl isatin in water was exposed to UV irradiation for 6 hours at a
distance of 2 cm and set aside for another 9 hours. The resulting UV irradiated
material was subjected to HPLC and GC/MS analysis to identify the chemical
species created upon irradiation.
The HPLC chromatogram of N-methyl isatin and the irradiated sample are
shown in Figure 22. As shown, N-methyl isatin had a retention time of 20 minutes
by HPLC. HPLC of the irradiated sample showed two peaks with retention times
of 20 and 22 minutes, respectively, as shown in Figure 24.

The peak at 20

minutes represented unreacted N-methyl isatin, whereas the peak at 22 minutes
represented a new compound.
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Figure 25: Top: HPLC analysis of the UV irradiated N-methyl isatin. The
peak at 20 minutes is N-methyl isatin and the peak at 22minutes
corresponds to N-methyl isatoic anhydride. Bottom: HPLC chromatogram
showing pure, authentic N-methyl isatin.
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Figure 26. (Top) Gas chromatogram of UV irradiated N-methyl isatin; (Middle)
Mass spectra of 6.49 peak; (Bottom) Mass spectra of 7.23 peak.
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To determine the chemical composition of the new material, we conducted
a GC/MS analysis (Figure 25) of the irradiated sample. Once again, two peaks
were observed. Mass spectrometric analysis and GC analysis with an authentic
sample, revealed that the peak at 6.49 minutes is N-methyl isatin and the peak at
7.23 minutes is N-methyl isatoic anhydride (see Figure 25). To examine the rate of
formation of N-methyl isatoic anhydride from N-methyl isatin, we conducted a
kinetic study. Irradiation of N-methyl isatin in THF followed by analyzes of the
samples at 2-3 hour intervals revealed the slow increase in the 7.2 minute peak.
Clearly, the rate of formation of the anhydride in THF is much slower than that
observed for the reaction in water.
In addition to the slow rate of formation, we also observed that the
concentration of the anhydride (as measured by the intensity of the 7.2 minute
peak) is smaller than when N-methyl isatin was irradiated in water (compare
figures 25 and 26). This result suggests that water and dissolved oxygen in the
water may play a role in the formation of the N-methyl isatoic anhydride. To
investigate this hypothesis, we conducted an UV-irradiation experiment of Nmethyl isatin in freshly distilled THF in a sealed PCR tube. Irradiation over 6 hours
did not result in the formation of any N-methyl isatoic anhydride (Figure 26). This
experiment indicates that water and oxygen are likely involved in the conversion of
isatin to isatoic anhydride in presence of UV radiation.
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Figure 27. Left: N-methyl isatin was irradiated in wet THF. The gradual
increase in the 7.2 peak (due to N-methyl isatoic anhydride) with increase in
time of exposure to UV radiation indicating the formation of isatoic
anhydride is time dependent.
Right: GC/MS chromatogram of UV irradiation of N-methyl isatin in freshly
distilled THF. The chromatogram shows no peak at 7.2 corresponding to Nmethyl isatoic anhydride after 6 hours of UV exposure.

Based on the above experiments, we conclude that UV irradiation converts isatin
to isatoic anhydride (Scheme 9).
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Scheme 6. Photochemical turnover of N-methyl isatin to N-methyl isatoic
anhydride

Given the above data, we propose that 15 is transformed into the highly
reactive anhydride (15b) as shown in Scheme 7. By dissolving compound 15 in
water and upon UV irradiation, the diazirine moiety converts into a carbene. The
carbene is highly reactive and unstable. The carbene reacts with the surrounding
protein. Then, after some time, the isatin moiety of 15 undergoes transformation
into isatoic anhydride as shown in Scheme 7. Once the anhydride is made, it
reacts with the protein to generate crosslinked protein.
Scheme 7. Proposed transformation of 15. Upon UV irradiation of 15 in
water. The generated carbene and isatoic anhydride might have involved
intercrosslinking of monomers of N5-CAIR synthetase.

59

Previous researchers who have investigated isatoic anhydride and related
molecules have shown that these molecules can readily react with lysine, serine
and cysteine residues.63-66 In order to verify this chemistry, we conducted a model
reaction with isatoic anhydride and benzyl alcohol (Scheme 8). We observed 21 as
the sole product in the reaction (Figure 27). This model reaction indicates that
isatoic anhydride readily reacts with alcohols and further supports the role of
isatoic anhydride as a reactive group capable of participating in the crosslinking of
N5-CAIR synthetase monomers.
Scheme 8. Reaction of isatoic anhydride with benzyl alcohol

Figure 28. Left: GC analysis of the reaction shown in scheme 8. The
anhydride (19) is completely consumed and the peak at 6.34 corresponds
to benzyl alcohol (20). Right: Mass spectra of 8.42 peak showing m/z
241.59, corresponding to 21.
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2. 2. 9. LC-MS/MS analysis of the photocrosslinked protein
With an understanding of the photochemistry of 15, we next sought to
determine the binding site of 15, and by extension, 7. To do this, we turned to
proteomic studies on the crosslinked N5-CAIR synthetase. N5-CAIR synthetase
was treated with 15, irradiated by UV light and then purified by SDS-PAGE. The
individual 84 and 42 kDa bands from the gel were excised, treated with
iodoacetamide to modify cysteine residues and then digested with either trypsin or
and chymotrypsin. The digested samples were subjected to LC-MS/MS analysis
(Proteomic Core Facility, Wayne State University). An examination of the
proteomic data indicates that we have 80 to 95 percent coverage (depending upon
the protease used) of the protein in all samples. Based on our understanding of
the photochemistry and reactivity of 15, we searched the proteomic data for a
261.16 modification. This modification represents an instance in which the
anhydride reacts with the protein, but the carbene has been quenched with water.
We found 73 separate instances where Ser227 was modified in the peptide
NVSDAINQKAQEL. This result suggests that Ser227 may be in the allosteric
binding site.
The above analysis does not explain the observed dimerization by 15 nor
does it indicate if the Ser227 modification is due to a non-specific reaction with 15.
To gain knowledge of the binding site of 15 and the peptides responsible for the
dimerization, we compared all experimentally determined peptides that we
obtained through proteolysis of the 42 kDa and 84 kDa bands. Surprisingly, we
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have found that only two peptides were missing in the 84 kDa
Da band. All other
peptides from the N- to the C
C-terminus
terminus could be accounted for. Interestingly, the
two peptides were located in the same region as sserine227.
erine227. The two peptides
pep
are
KAQELARKAVAAFDGKG and KLVYAPARNVSDAINQKA.

Figure 29. Top: N5-CAIR
CAIR synthetase with the missing peptides shown in
red. Ser 227 is shown in green.
Bottom: N5-CAIR
CAIR synthetase shown as dimer with the missing peptides
shown in red. The two monomers of the enzyme are shown in green and
cyan. The modified serine residue is shown in yellow. It is evident from this
picture that the proposed binding site for 15 is not located at the dimer
interface.
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An examination of the location of these missing peptides in the crystal
structure of Aspergillus N5-CAIR synthetase reveals that there is no obvious
reason for the formation of a dimer during the photocrosslinking studies (Figure
28). The two missing peptides are 20 Å away from the dimer interface and the
linker on 15 is too short to span this distance. Thus, the only way for dimers of the
synthetase to form is the crosslinker bound to this site, would be if the enzyme
existed in a different dimer conformation than the one observed in the crystal
structure. This result hints at the existence of multiple conformations in the dimer
formation of the synthetase.

Others have observed conformational crosstalk

between distal sites on ATP-grasp enzymes and the active site.45 Given this, it is
possible that 7 functions by binding to and stabilizing an alternative conformation
which is inactive. Additional studies will have to be conducted to validate or refute
this hypothesis.

63

Chapter 3
Discussion
3.1. Structural and functional studies on N5-CAIR synthetase:
Previous NMR, biochemical and kinetic studies demonstrated that N5-CAIR
synthetase generated the unstable product N5-CAIR from AIR using ATP and
bicarbonate.23 Based upon literature precedence for ATP-utilizing carboxylation
enzymes, Stubbe and coworkers proposed that N5-CAIR synthetase proceeds
through the formation of the highly unstable intermediate carboxyphosphate.23
Subsequent positional isotope incorporation studies supported this hypothesis.23,
67, 68

The formation of carboxyphosphate has been proposed for other ATPgrasp enzymes that utilize bicarbonate as a one-carbon substrate. The two best
studied examples are biotin carboxylase69 and carbamoyl phosphate synthetase70,
71

(Figure 29).

Both enzymes catalyze a reaction that is analogous to that

conducted by N5-CAIR synthetase; namely, ATP reacts with bicarbonate to
generate carboxyphosphate, which is either directly attacked by a nucleophile or
decomposes to CO2 before attack by a nucleophile onto the generated CO2.
One approach towards understanding the chemistry of these enzymes is to
examine their half-reactions (Figure 8).

The first half reaction is the reaction

between ATP and bicarbonate to generate carboxyphosphate and ADP. Both
biotin carboxylase and carbamoyl phosphate synthetase are able to catalyze the
transfer of phosphate to the carboxylic acid in the absence of the nucleophilic
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substrate.50, 57, 69 In keeping with the expected similarities between these enzymes
and N5-CAIR synthetase, we have found that N5-CAIR synthetase will catalyze the
bicarbonate-dependent hydrolysis of ATP in the absence of AIR. This result, in
conjunction with the results published from the laboratory of Professor Stubbe,
support the hypothesis that carboxyphosphate is an intermediate in the reaction.

Figure 30. Top: mechanism of biotin carboxylase; Middle: Mechanism of
carbamoyl phosphate synthetase; Bottom: Mechanism of N5-CAIR
synthetase. All the three enzymes show production of carboxyphosphate
intermediate.

The second half-reaction deals with the fate of carboxyphosphate. There is
much debate regarding this question and two mechanisms have been proposed.69,
72

The first proposed mechanism is that carboxyphosphate is the electrophile for

the carboxylation reaction and is directly attacked by the nucleophilic substrate.
The second proposed mechanism is that carboxyphosphate dissociates to CO2,
which is the true electrophile in the reaction.
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Figure 31. Possible fate of carboxyphosphate during carboxylation reaction.
We have initiated a variety of studies to attempt to address this issue for N5CAIR synthetase.

We began with an exploration of the structures N5-CAIR

synthetase containing various ligands. Of particular interest were the structures of
N5-CAIR synthetase in the presence of ATP and ADP:Pi since these structures
provide information on the active-site architectures before and after ATP
hydrolysis.

The location of the inorganic phosphate provides a good

approximation of the location of the carboxyphosphate binding site and we next
attempted to model carboxyphosphate into this location.
Although carboxyphosphate has been postulated as a key intermediate in a
number of reactions, few computational studies have been done on this
compound.

The first step in the formation of carboxyphosphate is the attack of

bicarbonate on the ɣ-phosphorus atom of ATP.

Herschlag et al studied

phosphoryl-transfer reactions to bicarbonate and indicated that an intermolecular
hydrogen bond between the proton on bicarbonate and one of the oxygen atoms
of phosphate stabilized the transition state.53 This suggests that the transition state
and carboxyphosphate likely exists in a pseudo-chair conformation (Scheme 6),
which is stabilized by a hydrogen bond between the proton on the acid and one of
the oxygens on the phosphate. To investigate the stability of this conformation, we
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initiated

quantum

mechanical

calculations

on

various

conformations

of

carboxyphosphate. We found that the pseudo chair conformation was 13 kcal/mol
more

stable

than

the

extended

conformation.

This

suggests

that

carboxyphosphate likely adopts a pseudo-chair conformation in the active site.
The next question deals with the fate of the proton on bicarbonate. It is
important to recall that N5-CAIR synthetase utilizes bicarbonate and not carbonate
and thus the proton on bicarbonate must be removed.

The pseudo-chair

conformation of carboxyphosphate suggests an answer to this problem. In the
pseudo-chair conformation, it is possible that the phosphate group on
carboxyphosphate can act as intramolecular base to remove the proton from the
carbonyl carbon. Such an intramolecular proton transfer has been observed in the
decomposition of carbamoylphosphate.56 Quantum mechanical calculations on the
proton-transfer reaction reveal that the proton prefers to be located on the
phosphate group by about 4 kcal/mol. If such a proton transfer were to occur, one
would expect that the leaving group would be HPO4-2 instead of PO4-3. While we
do not know whether this is the case for N5-CAIR synthetase, previous studies on
biotin carboxylase indicates that HPO4-2 is indeed the product that is released from
the enzyme.57
With the above studies completed, we could now generate a model of
carboxyphosphate bound to N5-CAIR synthetase. To do this, we superimposed the
phosphate group of the pseudo-chair conformation of carboxyphosphate onto the
experimentally observed inorganic phosphate in the ADP:Mg:Pi structure of N5-

67

CAIR synthetase from E. coli. To generate a model of carboxyphosphate with AIR
bound, we took the carboxyphosphate modeled structure and superimposed the
Aspergillus

clavatus

ADP:AIR

crystal

ADP:Mg:carboxyphosphate:AIR model.

structure

to

generate

the

final

It is important to note that in these

models, the superimposed structures displayed less than a 1 Å difference for the
alpha carbon atoms of the peptide backbone, and the superimposed structures of
ADP were less than 0.5 Å different. Given these modest differences, we are
confident that our model represents an accurate snapshot of the active site during
catalysis.
According to our model, the carboxyl group of carboxyphosphate is
approximately 4 Å away from N5 of AIR. This distance is longer than would be
expected for a direct attack on the carbonyl group. Furthermore, the angle of
attack of the amine on the carboxyl group is not ideal. The attacking nucleophile,
AIR, should come in at a 107o angle to the carbonyl carbon to maintain the
tetrahedral transition state during reaction.73 But in this model, the orientation of
the carbonyl carbon of carboxyphosphate with respect amine of AIR is less than
90o. The interesting feature of this model is that the carbonyl oxygens of the
carboxyphosphate were beautifully placed between Lys353 and Arg271, two
conserved residues in the active site of N5-CAIR synthetase. These observations,
in

addition

to

the

computational

and

quantum-mechanical

studies

on

carboxyphosphate, suggested to us that it is unlikely that AIR directly attacks
carboxyphosphate. Thus, we propose that carboxyphosphate decomposes to CO2
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and HPO3-2 and the resulting CO2 group is then in the correct position for favorable
attack by AIR.
If this hypothesis is correct, the enzyme should stabilize CO2 within the
active site and should catalyze the reaction between CO2 and AIR. Experiments to
investigate this hypothesis reveal the turnover of AIR by N5-CAIR synthetase in
the presence of high bicarbonate concentrations (to generate CO2) but in the
absence of ATP. This experiment demonstrates the second half-reaction of the
enzyme, namely AIR and CO2 to generate N5-CAIR. This experiment is important
because it directly addresses a key mechanistic issue and such a reaction has not
been demonstrated for the other ATP-grasp carboxylation enzymes.
To gain more information on the mechanism of the reaction and on the
binding site for AIR, we initiated site-directed mutagenesis experiments.

The

availability of the crystal structures of N5-CAIR synthetase from Aspergillus
clavatus and E. coli provided us with a good platform to start these studies. We
mutated five residues (D153, R155, Y152, E73, and K353) to alanine and in all
cases, the mutant enzymes displayed decreased catalytic proficiency. The Km for
AIR for the mutant proteins increased, but surprisingly, for most, the Kd for AIR
remained either unchanged or decreased.
A mutant which is of interest is Glu73. Glu73 makes hydrogen bonding
interactions with the 2’ and 3’ hydroxyl groups of AIR and is away from the
catalytic site. Mutation of Glu73 resulted in decrease in Kd and 1,400-fold
decrease in kcat. We were surprised to see this result. Careful evaluation of the
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crystal structure reveals that Glu73 lies in the same loop as Glu75. Glu75 in turn
makes hydrogen-bonding interactions with Arg271, which lies in the active site. As
mentioned above, we believe that Agr271 plays an important role in binding and
stabilization of carboxyphosphate. We speculate that in the absence of Glu73, the
orientation adopted by Glu75 might not be optimal for hydrogen bonding to
Arg271.

This, in turn, alters the conformation of Arg271, which disrupts the

interactions made by this residue with carboxyphosphate.
One of the objectives of the site-directed mutagenesis study was to identify
the active-site base used in catalysis. Based upon our model presented above,
either Asp153 or Lys353 could function as the base. Both residues are strictly
conserved in 100 aligned N5-CAIR synthetase amino acid sequences deposited in
databanks to date40. Structural information from the Mg:ADP:AIR crystal structure
shows that Lys353 is approximately 4 Å away from the exocyclic amine of AIR,
whereas Asp153 lies less than 3 Å away and is hydrogen bonded to the exocyclic
amine of AIR. Mutation of Asp153 results in an enzyme with essentially the same
Km and Kd as the wild-type enzyme, but with a kcat value more than 1,600-fold
lower. It is evident from this result that Asp153 is involved in catalysis, but not in
binding. Mutation of the Lys353 resulted in an inactive protein that was still
capable of binding AIR with the same affinity as the wild-type enzyme. According
to our model, Lys353 should play an important role either in the formation or
decomposition of carboxyphosphate.

Given this important function, it is not

surprising that loss of Lys353 may lead to an inactive enzyme. Thus, we propose
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that Lys353 is not the active-site base and suggest that Asp153 assumes this
function during catalysis.
Taken together, we propose the following mechanism for N5-CAIR
synthetase

(Figure

carboxyphosphate.

13).

Bicarbonate

reacts

with

ATP

to

generate

Carboxyphosphate, with the aid of Lys353 and Arg271

decomposes to CO2 and HPO4-2. These same residues serve to hold CO2 near the
site of attack and active it. In a concerted reaction, the N5 of AIR is deprotonated
by Asp153 as it attacks CO2 to generate the product N5-CAIR. The resulting
negative charge on the carbamate is neutralized by either Lys353 or Arg271.
Our proposed mechanism is similar to that suggested for other ATP-grasp
carboxylases.

Kinetic experiments

conducted by Tipton et al.,

showed

bicarbonate-dependent and biotin independent activity for biotin carboxylase57,
which indicates that bicarbonate attacks ATP and forms a carboxyphosphate
intermediate. They also showed that the dianion of phosphate is released from the
enzymatic reaction, which is consistent with our computational studies of the
pseudo-chair conformation of carboxyphosphate and subsequent release of
carbon dioxide from carboxyphosphate. Recently, Chou et al determined the
crystal structure of biotin carboxylase with bicarbonate bound in the active site.74
In the crystal structure (PDB: 3G8C), one of the oxygen atoms of bicarbonate is
located in the correct position to initiate a nucleophilic attack on ATP to form the
carboxyphosphate intermediate and the bicarbonate is in hydrogen bonding
distance with Lys238 and Arg292.74 It is important to point out that both biotin
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carboxylase and N5-CAIR
CAIR synthetase utilize a lysine and arginine in the
bicarbonate site. At physiological pH both of these residues exist as positively
charged species and may promote the dissociation of carboxyphosphate
intermediate, as we proposed in the case of N5-CAIR synthetase (Figure
ure 31).

Figure 32. Biotin carboxylase with bicarbonate and ADP in the crystal
structure.74 The protein in shown in grey ribbon representation while biotin,
bio
bicarbonate and ADP is shown in stick representation with green carbons.
In reactions catalyzed by the carbamoyl phosphate synthetase, after
formation of carboxyphosphate, ammonia (derived from glutamine) is carboxylated
to form carbamate. Another AT
ATP then phosphorylates the carbamate to form
carbamoyl phosphate50. Like the biotin carboxylase reaction, it is uncertain
whether carboxyphosphate or CO2 is the carboxylating
xylating species. Gibson et al.
studied the bicarbonate-dependent
dependent ATPase reaction catalyzed by carbamoyl
phosphate synthetase in the absence of glutamine/ammonia.. They showed that
the initial rate of bicarbonate
bicarbonate-dependent ATP cleavage was faster than the
nonenzymatic rate of CO2 hydration
hydration.72 Given this, these investigators believed that
if CO2 was liberated
ted during catalysis, it should be observable. A variety of
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experiments including pH sensitive and

13

C-NMR experiments failed to detect the

presence of enzyme-generated carbon dioxide.72 Based upon this negative result,
the investigators concluded that carboxyphosphate must be the carboxylating
species in carbamoyl phosphate synthetase. However, since they were studying
only the half reaction, the ammonia channel in the enzyme active site could be
occupied by water and the rate of hydration of CO2 might been enhanced because
it occurred in the active site. If this happened, then it is unlikely that there would
have been sufficient CO2 available for detection.
Taken together our structural, functional, kinetic and computational studies
suggest that N5-CAIR synthetase proceeds through carboxyphosphate. We
suggested that carboxyphosphate predominantly exists in a pseudo-chair
conformation and that this intermediate dissociates to CO2 by intramolecular
proton transfer from carbonyl carbon to phosphoryl oxygen. The released CO2 is
stabilized by Lys353 and Arg271.
3.2. Identification of inhibitors for N5-CAIR synthetase through HTS:
One potential, but unexplored, target in antimicrobial drug design is de novo
purine biosynthesis. Since all cells require nucleic acids, growth of rapidly dividing
cells can be inhibited by preventing the production of nucleotides.75, 76 Biochemical
and genetic studies have shown that de novo purine biosynthesis is different in
microbes than in humans.23 The divergence in the pathway is centered on the
synthesis of CAIR. In microorganisms, purine biosynthesis requires the enzyme,
N5-CAIR synthetase. This enzyme is absent in humans.23 Genetic studies support
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the critical role of this enzyme in microbial growth. The enzyme has been identified
as a virulence factor and mutations that inactivate the enzyme renders microbes
nonvirulent.28, 33 The uniqueness of N5-CAIR synthetase suggests that it is a safe
target for the design of antimicrobial agents.
Despite the biochemical rationale for targeting biosynthesis, does inhibiting
this pathway make sense? As noted in the introduction, there are two pathways
for the synthesis of purines in most microorganisms. These pathways are the
salvage pathway and the de novo pathway. Previous biochemical studies have
shown that in the absence of de novo purine biosynthesis, microbes usually
operate under salvage pathway.77 However, the salvage pathway produces only a
small amount of the total quantity of purine nucleotides within the cell (less than
1%) and it is highly dependent upon an exogenous source of purines. While the
exact concentration of purines in different tissues is difficult to know, it is generally
believed that the concentration is below 1.5 µM.78,
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Thus, biochemical systems

that require a large amount of nucleotides (i.e. DNA and RNA synthesis), would be
rendered inactive due to the lack of basic “building” materials. However, it is
important to recognize that inhibition of de novo purine biosynthetic pathway would
provide only a bacteriostatic affect to the microorganism. It is also crucial to point
out that not all microbes depend on the de novo purine biosynthetic pathway for
their nucleotide requirements. For example Mycobaterium80 and Plasmodium81
species do not have the pathway and they largely depend upon the salvage
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pathway and exogenous purines for their survival. Thus, in these cases, purine
biosynthetic pathway inhibitors would be ineffective in controlling these infections.
The utility of targeting the de novo purine pathway can be demonstrated by
agents that inhibit other enzymes within the pathway. The first efforts to inhibit the
purine biosynthetic pathway were started in 1948 by Elion and coworkers.75 This
group designed 2,6-diaminopurine as an antimetabolite for the purine biosynthetic
pathway and they found that the compound strongly inhibited the growth of L.
casei76. They also found that the inhibition was reversed by the addition of adenine
to the growing cultures. Excited by this finding, the Elion group intensified the
search for more

potent

inhibitors

of

the

pathway and

discovered

6-

mercaptopurine.75 Studies revealed that 6-mercaptopurine was an antimetabolite
of

hypoxanthine

and

is

a

substrate

for

the

enzyme

hypoxanthine

phosphoribosyltransferase.75 The principal sites of action appear to be feedback
inhibition of de novo purine synthesis, inhibition of inosine dehydrogenase, and
incorporation into DNA in the form of thioguanine.
De novo purine biosynthesis contains two folate-utilizing enzymes.
Inhibitors of folate utilizing and metabolizing enzymes are well known and these
agents have provided the foundation for the development of inhibitors for the
formyl-transfer reactions found in purine biosynthesis. In an effort to inhibit the N10formyltetrahydrofolate-dependent GAR transformylase, Marsilje and Cheng et al.
designed and synthesized N10-formyltetrahydrofolate-mimicking agents (22 and
23). These agents are potent inhibitors of the human GAR transformylase and
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display exceptional cytotoxic activity.82-85 To date, there have been no selective
inhibitors of microbial transformylase enzymes.82, 85

At the beginning of this project, there were no known, small molecule
inhibitors of N5-CAIR synthetase. To identify inhibitors, we screened 48,000 druglike compounds using a phosphate-sensitive molybdate assay. This assay is
based on the reaction of phosphomolybdate with the dye malachite green, and has
been used previously to assay protein tyrosine phosphatase86, phosphoinositide
phosphatases87, and myosin ATPase.88 Our work is the first to report the use of
this assay to screen a compound collection for inhibitors of N5-CAIR synthetase.
The assay was reproducible (Z’ >0.7), cost effective, suitable for automation, and
easily converted from 96- to 384-well plates.
Using the above assay, we identified the first selective, non-nucleotide
inhibitors of N5-CAIR synthetase. These compounds inhibited the enzyme in the
range of 30–120 µM and follow Lipinski’s rules. The compounds were classified
into three distinct classes based on structural similarity. Members of class I
contained an indenedione group, which upon incubation in water resulted in the
production of ninhydrin that reacted with the substrate AIR. Since these
compounds are present in commercial chemical libraries, researchers conducting
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HTS should be aware of the potential of these compounds to decompose and
react with amines present in the substrate.
Compounds belonging to class II are ideal lead agents in that they display
non-competitive kinetics with respect to both AIR and ATP. Such a feature is
necessary for agents targeting an enzyme in the middle of a biosynthetic pathway
since increases in the concentration of the substrate could not overcome inhibition
by the drug. Class II compounds are small (approximately 250 atomic mass units)
and thus provide flexibility to build additional binding features into the molecule to
enhance potency. For example, we have successfully introduced a diazirine
moiety into these molecules without losing inhibitory activity (compound 15).
The non-competitive kinetics of class II molecules could indicate that these
agents recognize a unique binding pocket on the enzyme. Interestingly, HTS of
other members of the N5-CAIR synthetase superfamily (ATP-grasp superfamily)
has identified compounds that regulate activity and bind to sites distinct from the
active site. For example, the natural product soraphen A inhibits acetyl-CoA
carboxylase by binding to a pocket some 25 Å away from the active site.45 Binding
to this location is thought to disrupt protein dimer formation resulting in inactivation
of the enzyme. HTS against S. aureus Dala:D-ala ligase also identified a noncompetitive inhibitor that bound very near the active site and precluded binding of
both ATP and D-alanine58, respectively.
Compound 13, which belongs to class III inhibitors, displays competitive
kinetics with respect to AIR. This suggests that 13 binds at or near the AIR-binding
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site. The uncompetitive nature of 13 with respect to ATP is interesting because it
indicates that the inhibitor binds only to the enzyme:ATP complex. Given that 13 is
competitive with AIR and thus likely binds to the AIR binding site, this suggests
that N5-CAIR synthetase may function via an ordered kinetic mechanism with ATP
binding first followed by AIR. Once both substrates are bound, catalysis occurs.
Additional kinetic studies are necessary to validate or refute this conclusion.
In our HTS, we purposely kept the concentration of ATP high to prevent the
identification of inhibitors that bound to the ATP site. We reasoned that
compounds that competed with ATP would be non-selective. However, a recent
study conducted by Miller et al. suggests that this hypothesis may be incorrect89.
Miller et al. conducted a bacterial whole-cell screening study to identify
compounds with antibacterial properties. They screened a library based upon a
protein

kinase

pharmacophore

and

found

a

series

of

antibacterial

pyridopyrimidines. The pyridopyrimidines were effective in vitro and in vivo against
fastidious

Gram-negative

pathogens

including

Haemophilus

influenza.89

Subsequent studies on one of the pyridopyrimidines (24 and 25) found that 24 and
25 targeted the ATP binding site of biotin carboxylase.89-91 As we have mentioned
previously, biotin carboxylase is a member of the ATP-grasp superfamily and is
related to N5-CAIR synthetase. The identification of potent and selective inhibitors
of biotin carboxylase is important, because it indicates that the ATP-binding site of
the ATP-grasp superfamily of enzymes is distinct from that of other ATP-binding
sites found in eukaryotic protein kinases and other ATP-utilizing enzymes. Given
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this discovery, it is easy to envision efforts to target the ATP-binding site of N5CAIR synthetase as a means to develop new antimicrobial agents targeting purine
biosynthesis.

3.3. Identification of the binding site for class II inhibitors:
Kinetic studies on class II inhibitors, typified by 7, revealed that these
agents displayed non-competitive kinetics with respect to both AIR and ATP. The
non-competitive nature of these inhibitors makes them attractive lead agents
because they are immune to the increase in substrate concentration that would be
expected when inhibiting an enzyme in the middle of a biosynthetic pathway.
However, since non-competitive inhibitors frequently do not bind to the active site,
structural studies become necessary to aid optimization of the inhibitor. Thus, it
became a priority to determine the binding site for class II inhibitors.
Given the fact that the structure of N5-CAIR synthetase has been solved,
we initiated a project that attempted to determine the structure of the
inhibitor:enzyme complex. Unfortunately, the poor aqueous solubility of the class II
inhibitors prevented the determination of the structure.

To circumvent this

problem, we chose to use a photoreactive derivative of the class II inhibitor, 7, to
label the binding site. Once this was accomplished, the location of the binding site
could be determined by LC/MS/MS methods. The use of photoaffinity molecules to
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modify the site of interaction has been very effective in providing information
about the location of binding sites.60 We synthesized 15 and conducted
photocrosslinking studies with N5-CAIR synthetase. SDS-PAGE analysis of these
studies revealed the presence of an 84 kDa band in addition to the expected 42
kDa band. Protein sequence analysis of the 84 kDa band demonstrated that it was
N5-CAIR synthetase. Thus, two monomers of N5-CAIR synthetase were
crosslinked. In order for this to occur, two photoactive groups must be present in
15. Subsequent experiments showed that the istatin group in 15 was converted
into isatoic anhydride, which presumably reacted with the protein.
The conversion of isatin into isatoic anhydride has been demonstrated in
the literature using a variety of conditions containing either peroxide or chromium
oxidants.92,
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However, there has been little mention of the photochemical

conversion of isatin into the anhydride.

Previous researchers who have

investigated the photochemistry of isatin reported the photodecomposition of isatin
in benzene with the subsequent detection of very small amounts of isatoic
anhydride.94 These researchers proposed that isatin might be converted to a
diradical species that reacts with another isatin molecule to form isatoic anhydride.
In another report, the photoreaction of isatin resulted in the formation of isatic
acid (2-amino-phenylglyoxalic acid)95 and not isatoic anhydride .94
To resolve these issues and to understand the photochemistry of isatin, we
irradiated N-methyl isatin in water. We found that N-methyl isatin is cleanly
converted to isatoic anhydride as shown in Figure 23. Additional experiments in
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both “wet” and dry THF revealed that isatoic anhydride formed only in the
presence of water. We have not done definitive experiments excluding molecular
oxygen, but we believe that oxygen also plays a role in the conversion.

Our

mechanism for the synthesis of isatoic anhydride from isatin is shown in Figure 32.
In this radical mechanism, UV light generates an isatic radical that then attacks
oxygen. The resulting intermediate then undergoes ring expansion in a manner
similar to that for the Baeyer-Villiger reaction to generate the anhydride.92 This
mechanism also posits that hydrogen peroxide is formed, and previous
investigators have shown that hydrogen peroxide catalyzes the conversion of
isatin to isatoic anhydride.92

Figure 33. Proposed mechanism for the formation of isatoic anhydride from isatin
Once isatoic anhydride is formed, it must react with the protein for
crosslinking of the monomers to occur. Previous researchers have reported that
isatoic anhydride and its derivatives are reactive towards, lysine, serine and
tyrosine derivatives63,
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and Zhang et al. have used a fluorous-tagged isatoic

anhydride as a scavenger for amines in solution phase parallel syntheses.96 All of
these results are consistent with our studies regarding the reaction between isatoic
anhydride and benzyl alcohol.
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With our understanding of the photochemistry of isatin, we searched for
peptides in our LC/MS/MS data that had an increase in molecular weight of 261.
This molecular weight corresponds to a reaction with the protein at the isatin side
of the molecule and the reaction of water with the diazirine side. Examination of
the proteomic data revealed that serine 227 was modified several times indicating
that this residue may be in the binding site of the class II inhibitors. However,
serine 227 is not located at the dimer interface and thus cannot easily explain the
formation of the dimer. The distance between serine 227 and the dimer interface
of N5-CAIR synthetase is greater than 20 Å, yet the linker length of 15 is only 6 Å.
Examination of the peptides determined from the LC/MS/MS experiments revealed
that two peptides, KLVYAPAR and AVAAFDGKG are missing in the crosslinked
protein.

Interestingly,

Ser227

is

located

in

the

sequence,

KLVYAPARNVSDAINQKA, which contains one of the missing peptides. Mapping
of these missing peptides onto the crystal structure of N5-CAIR synthetase reveals
that neither peptide is near the dimer interface (Figure 28). If these peptides are
from the class II binding site, this would indicate that N5-CAIR synthetase exists in
multiple dimer conformations, only one of which has been crystallized. The
existence of multiple dimer conformations is well documented for other proteins.
For example, the transcriptional protein AraC undergoes dramatic dimer
reorganization upon binding of the sugar arabinose.97, 98
The possibility of multiple conformations for the synthetase could also be
important for the interaction of this protein with other enzymes in the purine
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biosynthetic pathway. Recent work by the Benkovic laboratory has demonstrated
the presence of a purisome complex in eukaryotic cells.25 The formation of a
multi-enzyme complex in purine biosynthesis has been speculated for years
because of the instability of many of the intermediates in purine biosynthesis.25
While

the

presence

of

the

purisome

has

not

been

demonstrated

in

microorganisms, there is a compelling argument for why it should exist. N5-CAIR
is one of the most unstable intermediates in purine biosynthesis. This compound
has a half-life of approximately one minute under physiological conditions and
decomposes to generate AIR.23 Thus, if the synthesis of N5-CAIR is not tightly
regulated, uncontrolled consumption of ATP occur. The presence of alternative
conformations of N5-CAIR synthetase, some of which are inactive, could provide a
solution to this problem. The presence of regulatory sites on N5-CAIR synthetase
is also supported by studies on other ATP-grasp enzymes.
polyketide,

For example, the

soraphen A, was discovered to be an allosteric inhibitor of biotin

carboxylase45. Interestingly, soraphen A inhibits the activity of the enzyme despite
the fact that it binds to the enzyme at a site that is ~20 Å away from the active site.
This observation supports the contention that there are conformational changes,
which regulate enzyme activity in ATP-grasp enzymes.
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Chapter 4.
CONCLUSION AND FUTURE DIRECTIONS
In this dissertation we have conducted studies aimed at understanding the
mechanism of N5-CAIR synthetase and identifying inhibitors of the enzyme. We
initiated this study because N5-CAIR synthetase is found only in bacteria, yeast,
and fungi, and thus is a ideal target for developing antimicrobial agents. Given the
critical need for novel antibacterial and antifungal drugs, we believe that studies on
this enzyme are needed to aid in the identification of agents that can inhibit this
enzyme.
We began our studies with collaboration with Dr. Hazel Holden on the
determination of the crystal structure of the enzyme from bacteria and fungi.
These studies provided important information on the active-site architecture in the
presence of various substrates and products. However, one critical intermediate
could not be experimentally determined. N5-CAIR synthetase, like all ATP-grasp
carboxylation enzymes is believed to proceed through formation of a
carboxyphosphate. The instability of this intermediate required that we generate a
molecular model of carboxyphosphate bound to the active site. However, once
carboxyphosphate has been formed, its fate is unclear. Some researchers believe
that carboxyphosphate dissociates to produce CO2, which is the true electrophile
of the reaction. Others believe that caboxyphosphate itself is the electrophile. For
N5-CAIR synthetase, a combination of structural, computational, and biochemical
experiments have lead us to conclude that CO2 is the electrophile in the reaction.
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Once carbon dioxide is generated, the exocyclic amine of AIR attacks it to
generate the product N5-CAIR.

Figure 15. Proposed mechanism for N5-CAIR synthetase. AIR and
carboxyphosphate are shown in red. The functional groups of the side
chains of amino acids believed to be involved in the mechanism are shown
along with the residue number.
Our second objective in this work was to identify inhibitors of N5-CAIR
synthetase. In order to accomplish this, we conducted high-throughput screening
on commercially available compound libraries at the Center for Chemical
Genomics located at the University of Michigan. We identified three classes of
inhibitors for the enzyme; however, only two sets of inhibitors turned out to have
properties useful for drug-discovery studies. One compound was competitive with
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AIR, and thus likely bound to the substrate-binding site of the enzyme. While
interesting, we chose not to focus on this compound because of potential
substrate competition issues. The remaining inhibitors were non-competitive with
both AIR and ATP. These inhibitors were also selective in that they do not inhibit
human AIR carboxylase, an enzyme evolutionarily related to the bacterial system.
To determine the allosteric binding site of these inhibitors, we synthesized a
diazirine photocrosslinking derivative and used this molecule to identify the binding
site by proteomic analysis. Interestingly, our data showed dimerization of N5-CAIR
synthetase

in

presence

of

the

photo

crosslinking

agent.

Subsequent

photochemical studies revealed that isatin in presence of water and dissolved
oxygen is converted to isatoic anhydride in the presence of UV light. This result is
a new finding for isatin chemistry.
The proteomic analysis of the photo crosslinked protein revealed that serine
227 was the residue modified by the photocrosslinking agent. Additional studies on
the photocrosslinked dimmer revealed that only two peptides were missing in the
dimerized protein indicating that these peptides might have in the binding site for
the inhibitor. However, examination of the location of these two peptides in the
crystal structure showed that the peptides are far away from the dimer interface of
the enzyme. Thus, if these two peptides are indeed in the inhibitor binding site, N5CAIR synthetase must exist in multiple dimer conformations.
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Areas of future research
The proposed mechanism for N5-CAIR synthetase is based upon indirect
evidence. To gather direct evidence, direct detection of CO2 released from the
carboxyphosphate will need to be done.

Examples of direct experimental

approaches include NMR and IR measurements. Both have been applied to the
study of carbon dioxide generating or utilizing enzymes.23, 72, 99 Other approaches
would include the use of CO2 mimics (i.e. COS, etc) to determine if these agents
inhibit the reaction or attempts to react various agents with CO2 to trap this
intermediate on the enzyme.
Future studies will also be needed to validate the binding site for the class II
inhibitors. One possible approach would be to utilize site-directed mutagenesis to
alter the binding site of the inhibitor. Mutants that prevent the ability of the class II
inhibitors from inhibiting the enzyme would suggest the binding site for the
compounds.
Future work can also be done on creating inhibitors of the ATP-binding site
of N5-CAIR synthetase. As noted in the discussion, recent research on inhibitors
of biotin carboxylase found a set of compounds which inhibit the enzyme while
binding to the ATP site. These studies suggest that the ATP-binding site of ATPgrasp enzymes may be fundamentally different than sites found in other classes of
enzymes. Studies on the ability of pyridopyrimidines to inhibit N5-CAIR synthetase
may be useful future investigations.

87

Chapter 5
MATERIALS AND METHODS

All chemicals, unless otherwise indicated were purchased from Thermo
Fischer Scientific, Aldrich or Sigma. N5-CAIR synthetase was obtained from
Professor Hazel Holden (University of Wisconsin, Madison) and stored at -80 oC.
The PurE and ADE2 genes were obtained from Professor Vincent Jo Davisson
(Purdue University, West Lafayette). Unless otherwise stated, all solutions were
stored at -20 oC. During all measurements, reagents and enzyme solutions were
stored in crushed ice. Measurements of pH were done using an Acumet basic
AB15 pH meter from Fischer Scientific. HPLC was conducted on a Waters 600
HPLC instrument using a PRP-1 column (Hamilton). Gas phase chromatographic
analysis was done using a Trace GC Ultra instrument with mass spectrometry
detection conducted with an ITQ900 instrument. Both instruments were obtained
from Thermo Scientific. Enzymatic assays were performed on a Varian Cary 3 UVvis spectrophotometer equipped with a temperature controller. All curve fitting was
conducted using the software, Kaleidagraph. NMR spectra were recorded using a
Varian 400 MHz spectrometer with deuterated solvents obtained from Cambridge
Isotopes.
5.1.

Cloning, expression, and purification of human AIR carboxylase and
bacterial N5-CAIR mutase:
The cloning of human AIR carboxylase and bacterial N5-CAIR mutase was

accomplished as follows. The human gene was amplified by PCR using primer I
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(5’-GGAATTCCATATGGCGACAGCTGAG-3’), which contains a NdeI site and
primer II (5’-GGGCTCGAGTAAATTACATTCTCTG-3’), which contains a XhoI site.
The bacterial gene was also amplified by PCR using primer III (5’GGGAATTCCATATGGTCTTCCCGCA-3’) which contains an NdeI site and primer
IV (5’-GGGCTCGAGTGCCGCACCTCGCGG-3’), which contains an XhoI site. The
purified PCR products were ligated into separate pGEM-T (Promega) vectors for
screening and sequencing. Both pGEM vectors were digested with NdeI and XhoI
to excise the N5-CAIR mutase and AIR carboxylase genes. Each gene was ligated
into a pET22b (Novagen) plasmid for protein expression. Expression from this
vector generated an N-terminal His-tag which contained the sequence
MGSSHHHHHHSSENLYFQGH at the beginning of the protein.
To express and purify the protein, each vector was transformed into E. coli
DE3 cells. A colony from each transformation was grown overnight in lysogeny
broth media at 37 ºC. The overnight culture was used to inoculate a 500 mL
culture and the culture was grown at 37 ºC with shaking until an optical density of
∼0.6 was measured at 600 nm. Protein expression was induced by the addition of
1 mM isopropyl β-D-1-thiogalactopyranoside and the induction was allowed to
proceed for 2 hours. The cultures were cooled to 4 ºC, the cells were collected by
centrifugation at 4 ºC and the cell pellets were stored frozen until use. To purify
the protein, cells were lysed with B-PER cell lysing reagent (Thermo Scientific)
and the resulting cellular debris was removed by centrifugation. The resulting
supernanant was loaded onto a cobalt nitrilotriacetic acid resin column (Thermo
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Scientific) and the column was washed with wash buffer (50 mM sodium
phosphate, 300 mM sodium chloride, 10 mM imidazole; pH 7.4). The protein was
then eluted with elution buffer (50 mM sodium phosphate, 300 mM sodium
chloride, 150 mM imidazole; pH 7.4). Purified N5-CAIR mutase and AIR
carboxylase were dialyzed against 10 mM Tris-HCl and 200 mM NaCl (pH 8).
Following dialysis, the sample was concentrated to ∼15 mg/mL and frozen in -80
o

C freezer.

5.2.

Kinetic analyses of wild-wype and mutant N5-CAIR synthetase:
The steady-state kinetic parameters for the wild-type and mutant enzymes

were determined using the ATP-coupled assay system as previously described

43,
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. In a 1 mL cuvette, buffer (50 mM HEPES (pH 7.5), 20 mM KCl, and 6.0 mM

MgCl2), 0.2 mM NADH, 2.0 mM phosphoenolpyruvate, 1.0 mM NaHCO3, 4 units of
pyruvate kinase, and 17 units of lactate dehydrogenase were added. After the
cuvette was equilibrated to 37 oC, N5-CAIR synthetase was added (the amount
varied depending upon the mutant protein) followed by 1.1 mM ATP. Background
levels of ATP hydrolysis were measured, and the reaction was initiated by the
addition of AIR (concentration varied from 5 to 500 µM). NADH oxidation was
monitored at 340 nm, and the concentration of AIR consumed was calculated
using the extinction coefficient for NADH (6200 M-1 cm-1). The background ATPase
activity was very low (<0.5%) and thus was not subtracted from the initial velocity.
The initial velocity of each reaction was determined during the first 2 min, and a
plot of initial velocity versus AIR concentration was generated. Kinetic parameters
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were determined by fitting multiple data sets to the Michaelis-Menten equation
using KaleidaGraph.
5.3.

Equilibrium dialysis of wild-type and mutant enzymes with substrate AIR:
The dissociation constant for AIR was determined by equilibrium dialysis.

To conduct these experiments, 200 µL of enzyme (final concentration of 10-12 µM
based upon a dimer molecular weight) in 50 mM HEPES (pH 7.5), 20 mM KCl,
and 6.0 mM MgCl2 buffer was added to six dialysis tubes (MWC of 8,000).
Simultaneously, six glass vials containing 1.5 mL of one of six AIR concentrations
(from 1 to 300 µM in the same buffer as the enzyme) were prepared, and the
absorbance of each solution was determined at 250 nm. The concentration of AIR
was determined using the published extinction coefficient of 3,270 M-1 cm-1. One
dialysis tube was added to each vial, and the vials were gently shaken for 16 h at
room temperature. After dialysis, the concentration of free AIR was determined by
the absorbance at 250 nm using the extinction coefficient listed above. The
concentration of bound AIR was determined by subtracting the amount of free AIR
from the total amount of AIR added at the beginning of the experiment. Control
experiments conducted in the absence of enzyme revealed no change in AIR
concentration, indicating that the substrate was stable over the course of the
experiment. Control experiments of the enzymes in the absence of substrate
revealed that they lost 10-20 % of their activity during shaking at room temperature
over the 16 h period. The dissociation constants and enzyme concentrations were

91

determined by fitting the data from a plot of the total amount of AIR versus the
amount of bound AIR to the quadratic equation (Equation 1).
5.4.

Bicarbonate-dependent ATPase activity of N5-CAIR synthetase:
The bicarbonate-dependent ATPase activity was measured as fallows. In a

1 mL cuvette, buffer (50 mM HEPES (pH 7.5), 20 mM KCl, and 6.0 mM MgCl2),
0.2 mM NADH, 2.0 mM phosphoenolpyruvate, 4 units of pyruvate kinase, and 17
units of lactate dehydrogenase were added. After the cuvette was equilibrated to
37 ºC, 28 µg of N5-CAIR synthetase was added followed by 1.1 mM ATP.
Background levels of ATP hydrolysis were measured, and the reaction was
initiated by the addition of NaHCO3 (concentration varied from 0 to 60 mM; the
background value of bicarbonate in solution was not considered). NADH oxidation
was monitored at 340 nm, and the concentration of ATP consumed was calculated
using the extinction coefficient for NADH (6,200 M-1 cm-1).
5.5.

Synthesis of N5-CAIR by N5-CAIR synthetase in the absence of ATP:
In a 1 ml total volume, buffer (HEPES 50 mM, KCl 20 mM, pH 7.8), 20 mM

HCO3-, 112 µg of enzyme were added. The reaction was incubated at 10 ºC for 3
minutes and background absorptions were measured. The reaction was initiated
by the addition of 0.5 mM AIR. The decrease in absorbance at 250nm was
monitored for the consumption of AIR. Control reactions consisted of AIR and
bicarbonate in the absence of enzyme and AIR and bicarbonate in the presence of
112 µg of bovine serum albumin (BSA).
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5.6.

Molecular modeling for determining CO2 binding site:
The location of AIR and ADP were experimentally determined from the

Aspergillus clavatus N5-CAIR synthetase crystal structure (PDB: 3K5I). E. coli N5CAIR synthetase (PDB: 3ETJ) was superposed on Aspergillus enzyme to
generate inorganic phosphate on the Aspergillus enzyme. The inorganic
phosphate binding site is the presumed binding site of carboxyphosphate. So, the
modeled carboxyphosphate was superposed on inorganic phosphate to generate
carboxyphosphate model in the active site.
5.7.

High-throughput screening of chemical libraries for inhibitors of N5-CAIR
synthetase:
High-throughput screening was conducted at the Center for Chemical

Genomics at the University of Michigan, Ann Arbor. The screening was conducted
as follows. Buffer was added to each well of a 384-well plate (50 mM HEPES, pH
7.5, 20 mM KCl, 6.0 mM MgCl2, 100 mM ATP, supplemented with a 1/100 dilution
of saturated NaHCO3) and 0.2 µL of a DMSO stock of each compound was added
to the plate using a Biomek FX pin tool such that the final concentration of the
compound in each well was between 5 and 27 µM. Each plate contained a column
of positive controls (enzyme + AIR + 0.2 µL of DMSO) and negative controls
(enzyme - AIR + 0.2 µL of DMSO). AIR (50 µM) was added to the appropriate
wells using a Thermo Labsystems Multidrop Micro plate dispenser followed by 168
ng of N5-CAIR synthetase. The reaction mixture was incubated at room
temperature for 5 min and was quenched by the addition of 6 µL of the malachite
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green reagent (Bioassay Systems) to each well. The plates were incubated at
room temperature for at least 15 min and then the absorbance (600 nm) of each
well was determined using a PHERA star (BMG Labs) plate reader.
5.8.

Dose-response analysis of hits from the high-throughput screen:
The dose response assays were conducted at the Center for Chemical

Genomics at the University of Michigan, Ann Arbor. The eight-point dose–
response assay uses the same protocol as the high-throughput assay except that
the concentration of each compound assayed was varied from 0.78 to 100 µM.
Each assay contained the same positive and negative controls used for the highthroughput screen. Data for compounds displaying a dose–response relationship
were curve fitted using the following equation (Equation 2) to determine the IC50
value.




  !" #$%&'

(2)

For equation 2, R is the response, N is the value of the negative control, P is the
value of the positive control, H is the Hill slope, and pIC50 is the negative logarithm
of the IC50.
5.9.

Kinetic analysis of inhibitors against N5-CAIR synthetase:
In a 1-mL cuvette, 50 mM HEPES, pH 7.5 buffer, containing 20 mM KCl

and 6.0 mM MgCl2, was added followed by 0.2 mM NADH, 2.0 mM PEP, 1.0 mM
NaHCO3, 4 units of pyruvate kinase, and 17 units of lactate dehydrogenase. To
the cuvette, 168 ng of N5-CAIR synthetase was added, followed by ATP and the
cuvette was incubated at 37 ºC for 3 min. For experiments in which ATP was held
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constant, the ATP concentration was 1.1 mM while the concentration of AIR was
varied from 5 to 250 µM. For experiments in which AIR was held constant, the AIR
concentration was held at 100 µM while ATP was varied from 5 to 250 µM.
Background levels of ATP hydrolysis were measured, and the reaction was
initiated by the addition of AIR and the inhibitor to be tested (0–50 µM). The
reaction mixture was incubated at 37 oC and NADH oxidation was monitored at
340 nm. The background ATPase activity was very low (<0.5%) and thus was not
subtracted from the initial velocity. The initial velocity of each reaction was
determined during the first 2 min, and a plot of initial velocity versus varied
substrate was generated. Lineweaver–Burke plots of each experiment were
constructed to determine the likely mode of inhibition. Secondary plots of the slope
versus inhibitor concentration were used to determine the Ki value for each
inhibitor. All graphing and curve fitting was done using KaleidaGraph.
5.10. Measurement of Minimum Inhibitory Concentrations (MICs):
MICs were determined in a liquid assay with E. coli NEB-5 cells growing in
variant bacterial (VB) medium. Exponential-phase cultures of E. coli (5µL) were
distributed in a 96 well plate containing 200 µL of VB medium. Each well was
treated with one drug concentration (0.1, 0.5, 1, 2, 4, 8, 16, 32, 64,128, 256, 512
µg/ml). In another well, ampicillin (100 µg/ml) was added as control. The plate was
incubated at 37 °C for 12 hours and then observed to d etermine cell growth. The
lowest concentration of drug that resulted in no visible growth was taken as the
MICs of the compound. To determine if growth inhibition could be rescued,
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cultures which were inhibited by the compound were treated with 1 mM of adenine
in water and incubated at 37 °C for 12 hours. Recover y of growth was again
determined visually.
5.11. Kinetic analysis of inhibitors against human AIR carboxylase:
Compounds 7, 13, and 14 were analyzed as inhibitors against the human
bifunctional enzyme using the coupled assay as previously described for the
Gallus gallus bifunctional AIR carboxylase:SAICAR synthetase100. In a 1 mL total
volume, 50 mM HEPES, pH 7.8, 0.05 µg of enzyme, and 25 mM MgCl2 were
preincubated for 5 min at room temperature. To the solution,100 mM KHCO3, 2.0
mM PEP, 1.0 mM ATP, 4.0 units of pyruvate kinase, 10 mM aspartic acid, and
0.24 unit of human bifunctional enzyme carboxylase:SAICAR synthetase were
added. The reaction was incubated at 37oC and was initiated by the addition of 0.5
mM AIR. After 1 minute monitoring the reaction 200 µL of 7, 13, and 14 were
added to the reaction and the reaction was continued to monitor at 282 nm for the
production of SAICAR.
AIR carboxylase was assayed as follows.43 In a 1 ml total volume, buffer
(Hepes 50 mM, KCl 20 mM, pH 7.8) and 0.05 µg of enzyme were added. The
reaction was incubated at 37 ºC and the inhibitor to be tested was added (200 µM).
The reaction was initiated by the addition of 0.5 mM CAIR and the conversion of
CAIR to AIR was monitored at 260 nm.
5.12. Synthesis of the photoscrosslinker 15:
1.10. A. tert-Butyl 3-(2,3-dioxoindolin-1-yl)propylcarbamate (16):
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To a stirred solution of isatin (2.71 mmol, 400 mg) and NaH (2.71 mM, 65
mg) in dry dimethylformamide, tert-butyl 3-bromopropylcarbamate (2.71 mM, 647
mg) was added dropwise under argon atmosphere. The reaction was stirred for 16
hours until TLC analysis (10% acetone in dichloromethane as the mobile phase)
revealed the disappearance of the starting materials. The reaction was evaporated
to dryness under reduced pressure and the solid residue was treated with water to
quench the reaction. The aqueous mixture was extracted with dichloromethane to
isolate compound 16. Compound 16 was purified by silica column chromatography
using 10% acetone in dichloromethane as the mobile phase. The appropriate
fractions were isolated, evaporated to dryness to generate a solid (yield: 95%). 1H
NMR (400 MHz, CDCl3) δ 1.405 (s, 3H), 1.415 (s, 3H), 1.437 (s, 3H), 1.880 (t, 2H,
J = 12 Hz), 3.159 (d, 2H, J = 5.2Hz), 3.775 (q, 2H, J = 6.4 Hz), 5.019 (s, 1H), 6.89
(m, 1H), 7.12 (m, 1H), 7.58 (m, 2H).13C NMR (100 MHz, CDCl3), δ 180.1, 161.9,
155.9, 148.1, 134.7, 117.7, 116.2, 125.7, 134.7, 79.5, 39.8, 37.4, 28.4. Ms
calculated for C16H20N2O4 is (M+H) is 305.14, fond 305.13
1.10.B.N-(3-(2,3-Dioxoindolin-1-yl)propyl)-3-(3-methyl-3H-diazirin-3yl)propanamide (15):
Compound 16 was added to a solution of HCl in ether (2 M, 2 ml) and the
resulting deprotection was allowed to run at room temperature for 10 hours. The
reaction was then evaporated under reduced pressure to generate the crude,
orange colored salt of 1-(3-aminopropyl) indoline-2, 3-dione. A small portion of the
material was kept aside for NMR analysis and the rest of the compound was
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utilized for the coupling of diazirine moiety without further purification. The salt of
1-(3-aminopropyl) indoline-2, 3-dione (0.2 mM, 50 mg) was added to 1 ml of dry
pyridine and stirred for 15 minutes. To the pyridine solution under argon
atmosphere, 2,5-dioxopyrrolidin-1-yl 3-(3-methyl-3H-diazirin-3-yl) propanoate (0.2
mM, 45 mg, Pierce Biotechnology) was added. The reaction mixture was stirred
for 16 hours and then evaporated under reduced pressure. The resulting residue
was washed with I N HCl to remove pyridine and the remaining crude material was
subjected to silica column chromatography using 10% acetone in dichloromethane
as the mobile phase. The product 15 was isolated in 80% yield.

1

H NMR (400

MHz, CDCl3): δ 1.043 (s, 3H), 1.785 (t, 2H, J = 7.2Hz), 1.925 (q, 2H, 5.6Hz), 2.061
(t, 2H, J = 7.6Hz), 3.26 (q, 2H, J = 6.4Hz), 3.825 (q, 2H, J = 6.4), 6.92 (d, 1H, J =
7.6Hz), 7.159 (m, 1H), 7.625 (m, 2H).

13

C NMR (100 MHz, CDCl3): δ 179.9, 172.6,

160.1, 148.1, 134.7, 129.9, 125.7, 116.7, 68.9, 44.8, 37.7, 39.8, 26.3, 26.1. MS
calculated for C16H19N4O3 is (M+H) 315.13, found 315.14.
5.13. Kinetic analysis of 15 against N5-CAIR synthetase:
In a 1-mL cuvette, 50 mM HEPES, pH 7.5 buffer, containing 20 mM KCl
and 6.0 mM MgCl2, was added followed by 0.2 mM NADH, 2.0 mM PEP, 1.0 mM
NaHCO3, 4 units of pyruvate kinase, and 17 units of lactate dehydrogenase. To
the cuvette, 168 ng of N5-CAIR synthetase was added, followed by ATP and the
cuvette was incubated at 37oC for 3 min. Background levels of ATP hydrolysis
were measured, and the reaction was initiated by the addition of AIR and the
inhibitor to be tested (0 and 90 µM). The reaction mixture was incubated at 37 ºC
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and NADH oxidation was monitored at 340 nm. The background ATPase activity
was very low (<0.5%) and thus was not subtracted from the initial velocity. The
initial velocity of each reaction was determined during the first 2 min, and a plot of
initial velocity versus varied substrate was generated. Lineweaver–Burke plots of
each experiment were constructed to determine the Vmax and Vmax app. The Ki value
was determined using equation 3 in which Vmaxapp is the maximal velocity obtained
from dose-response curve, Vmax is obtained from uninhibited curve and [I] is
inhibitor concentration.
()*+,-. /00 &12/+4/5

(3)

5.14. Photocrosslinking experiments with 15 and N5-CAIR synthetase:
To examine the ability of 15 to crosslink N5-CAIR synthetase, the following
experiment was performed. Into 3 separate PCR tubes, a 100 µl total of a solution
of phosphate buffered saline (50 µL of 0.1 M sodium phosphate, 0.15 M sodium
chloride, pH 7.2), N5-CAIR synthetase (100 µM), ATP (100 µM), and AIR (100 µM)
was added. One tube was set aside as a negative control. To another tube, 15
(100 µM) was added. To a third tube, 15 and 7 (100 µM each) were added. A
fourth tube containing phosphate buffer saline, enzyme and 15 was prepared. All
tubes were UV irradiated with an 110V UV lamp (model: B100AP, manufactured
by UVP Inc.) emitting radiation between 340-360 nM for 20 minutes. The distance
between the light source and the reaction was 5 cm. The reaction was analyzed
on a 12% SDS-PAGE gel and visualized by staining with Commassie Blue.
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5.15. Dose-dependent photocrosslinking studies of 15 with N5-CAIR synthetase:
In a 100 µL solution contained in PCR tubes, phosphate buffered saline (50
µL of 0.1 M sodium phosphate, 0.15 M sodium chloride, pH 7.2), N5-CAIR
synthetase (100 µM), ATP (100 µM), and AIR (100 µM), various concentrations of
15 (10 µM, 25, 50, 75 and 100 µM) were added. The PCR tubes were UV
irradiated with a 110 V UV lamp (model: B100AP, manufactured by UVP Inc.)
emitting radiation between 340-360 nM for 20 minutes. The distance between the
light source and the reaction was 5 cm. After UV irradiation, the reaction was
analyzed on a 12% SDS-PAGE gel and visualized by staining with Commassie
Blue.
5.16. Time-dependent inactivation kinetics of N5-CAIR synthetase with 7:
A solution of 7 (0.01 mmol, 5 mg) in DMF and subjected to UV irradiation
with a 110 V UV lamp (model: B100AP, manufactured by UVP Inc.) emitting
radiation between 340-360 nM for 2 hours. The distance between the light source
and the reaction was 5 cm. N5-CAIR synthetase (20 µM) was incubated on ice
with either the non-UV irradiated or the UV irradiated 7 (100 µM). Enzyme samples
from the two preparations were withdrawn at 1, 5, 15, 30, 60 and 120 minutes and
analyzed for the activity of the enzyme using the pyruvate kinase and lactate
dehydrogenase coupled assay system. The resulting enzyme activity was
compared to an enzyme control which did not contain any 7. The percent activity
was calculated at each time point by taking the ratio of the activity of the treated
sample versus the untreated sample.
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5.17.

Reversibility of the time-dependent inactivation of 7:
Solutions of either the non-UV irradiated or the UV irradiated 7 (100 µM)

incubated with N5-CAIR synthetase (20 µM) were incubated for 2 hours on ice.
The resulting solutions were then were dialyzed for 5 hours against 10mM TrisHCl, 200 mM NaCl (pH 7.2) buffer. After dialysis, the activity of the enzyme was
determined by the standard pyruvate kinase/lactate dehydrogenase assay system.
5.18.

Photochemistry of N-methyl isatin:
N-methyl isatin (0.124 mmol, 20 mg) was dissolved in 3 ml of THF in a

beaker. The beaker was UV irradiated for 2 hours from a distance of 3 cm with an
110 V UV lamp emitting radiation between 340-360 nm. After UV irradiation the
compound was analyzed by HPLC and GC/MS. HPLC separation of the UV
treated N-methyl isatin was done with a PRP-1 column (Hamilton)

using a

gradient of water:acetonitrile such that the gradient started at 0% acetonitrile and
proceeded to 100% acetonitrile over a period of 50 minutes. For GC/MS analysis
0.1 µg the compound was dissolved in 5ml CH2Cl2 and 1µL of the solution was
injected on to a GC column of Trace GC Ultra. The sample was vaporized at 250
º

C and the column was ramped from 80 to 300 ºC over 15 minutes. The peaks

obtained by GC analysis were identified by mass analysis using the ITQ900
detector. The identification of the new peaks was determined by comparison to
authentic samples.
5.19.

Reaction of N-methyl isatoic anhydride with benzyl alcohol:
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N-Methyl isatoic anhydride (0.28 mmol, 50 mg) was dissolved in dry DMF
and treated with benzyl alcohol (0.28 mmol, 30 mg) under argon atmosphere. The
reaction mixture was stirred at 55 ºC for 12 hours. After 12 hours, the DMF was
removed under reduced pressure by a rotary evaporator. The resulting residue
was washed with water and dried under vacuum. A sample of the material was
dissolved in dichloromethane and subjected to GC/MS analysis. The remainder of
the material was purified by silica column chromatography using 10% acetone in
dichoromethane as a mobile phase. The major material was isolated and dried in
vacuum to give a straw color liquid in 95% yield. 1H NMR (400 MHz, CDCl3): 2.914
(s, 3H), 4.638 (s, 1H), 5.331 (s, 2H), 6.65 (m, 2H), 7.44 (m, 6H), 8.013 (d, 1H, J =
8.4Hz).

13

C NMR (100 MHz, CDCl3): 165.9, 152.3, 136.1, 133.8, 130.7, 128.9,

127.6, 127, 113.2, 110.9, 65.7, 30.1. MS calculated for C15H15NO2 is (M+) 241.48,
found 241.59.
5.20. LC-MS/MS analysis of photocrosslinked proteins:
Proteomic analysis of the crosslinked proteins was conducted at the
proteomics core facility at Wayne State University. The appropriate band from the
SDS-PAGE gel was excised, reduced (DTT), alkylated (iodoacetamide) and
digested (trypsin or chymotrypsin) by an automated process (ProGest, Genomic
Solutions). The resulting peptides were dried and resuspended in a 5%
acetonitrile, 0.1% TFA solution. Peptides were purified with a CapTrap (Michrom)
and separated with an in-line Magic C18AQ 200A 3u 100Ux150mm nano-flow
column. Peptides were ionized with the ADVANCE ion source (Michrom) and
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introduced into an LTQ-XL mass spectrometer (Thermo Fisher Scientific).
Abundant species were fragmented with either collision-induced dissociation (CID)
or electron transfer dissociation (ETD).

Data analyses were performed using

BioWorks (Thermo), and Scaffold (Proteome Software) software that incorporated
SEQUEST, X!Tandem and ProteinProphet algorithms.
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APPENDIX: LIST OF ABBREVIATIONS
o

degrees centigrade

AIR

5-aminoimidazole ribonucleotide

ATP

adenosine triphosphate

CAIR

4-carboxy-5-aminoimidazole ribonucleotide

HEPES

N-(2-hydroxyethyl)-piperazine-N-(2-ethanesulfonic acid)

HPLC

high-performance liquid chromatography

LB

Luria-Bertani media

min

minute

mL

millilitre

NADH

dihydronicotinamide adenine dinucleotide

N5-CAIR

N5-carboxyaminoimidazole ribonucleotide

NMR

nuclear magnetic resonance

PAGE

polyacrylamide gel electrophoresis

PEP

phosphoenolpyruvate

PK

pyruvate kinase

s

second

SAICAR

4-[(N-succinylamino) carbonyl]-5-aminoimidazole

SDS

sodium dodecyl sulfate

TLC

thin-layer chromatography

Tris

tris-(hydroxymethyl)aminomethane

UV

ultraviolet

C
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ABSTRACT
ENZYMOLOGY AND MEDICINAL CHEMISTRY OF N5CARBOXYAMINOIMIDAZOLE RIBONUCLEOTIDE SYNTHETASE:
A NOVEL ANTIBACTERIAL TARGET
by
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AUGUST 2010
Advisor: Dr. Steven M. Firestine
Major: Pharmaceutical Sciences
Degree: Doctor of Philosophy
N5-Carboxyaminoimidazole

ribonucleotide

synthetase

(N5-CAIR

synthetase), a key enzyme in microbial de novo purine biosynthesis, catalyzes the
conversion of aminoimidazole ribonucleotide (AIR) to N5-CAIR. To date, this
enzyme has been observed only in microorganisms, and thus, it represents an
ideal target for antimicrobial drug development. Here, we report structural and
functional studies on the Aspergillus clavatus N5-CAIR synthetase and
identification of inhibitors for the enzyme. In collaboration with Dr. Hazel Holden of
the University of Wisconsin, the three-dimensional structure of Aspergillus clavatus
N5-CAIR synthetase was solved in the presence of either Mg2ATP or MgADP and
AIR. These structures, determined to 2.1 and 2.0 Å resolution, respectively,
revealed that AIR binds in a pocket analogous to that observed for other ATPgrasp enzymes involved in purine metabolism. On the basis of these models, a
site-directed mutagenesis study was subsequently conducted that focused on five
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amino acid residues located in the active site region of the enzyme. These
investigations demonstrated that Asp153 and Lys353 play critical roles in catalysis
without affecting substrate binding. All other mutations affected substrate binding
and, in some instances, catalysis as well. Taken together, the structural and
kinetic data presented here suggest a catalytic mechanism whereby Mg2ATP and
bicarbonate first react to form the unstable intermediate carboxyphosphate. This
intermediate subsequently decarboxylates to CO2 and inorganic phosphate, and
the amino group of AIR, through general base assistance by Asp153, attacks CO2
to form N5-CAIR.
To identify the inhibitors for this enzyme, we have conducted highthroughput screening (HTS) against Escherichia coli N5-CAIR synthetase using a
highly reproducible phosphate assay. HTS of 48,000 compounds identified 14
compounds that inhibited the enzyme. The hits identified could be classified into
three classes based on chemical structure. Class I contains compounds with an
indenedione core. Class II contains an indolinedione group, and class III contains
compounds that are structurally unrelated to other inhibitors in the group. We
determined the Michaelis–Menten kinetics for five compounds representing each
of the classes. Examination of compounds belonging to class I indicates that these
compounds do not follow normal Michaelis–Menten kinetics. Instead, these
compounds inhibit N5-CAIR synthetase by reacting with the substrate AIR. Kinetic
analysis indicates that the class II families of compounds are non-competitive with
both AIR and ATP. One compound in class III is competitive with AIR but
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uncompetitive with ATP, whereas the other is non-competitive with both
substrates. Finally, these compounds display no inhibition of human AIR
carboxylase indicating that these agents are selective inhibitors of N5-CAIR
synthetase.
Given the importance of the class II, non-competitive inhibitors, we
developed a diazirine-based photocrosslinking agent to identify the binding site of
these inhibitors. These studies revealed that the isatin core of class II inhibitors is
capable of undergoing photochemical conversion to isatoic anhydride. Once
formed, the anhydride is capable of reacting with the protein. Treatment of N5CAIR synthetase with the photoreactive agent lead to the dimerization of two
monomers of the synthetase.

Proteomic analysis of the crosslinked protein

identified serine 227 as a possible site of modification.

These studies also

revealed two peptides that were missing in the dimerized protein sample. These
two peptides were located near serine 227. While compelling, the location of the
missing peptides and serine 227 is 20 Å away from the dimerization interface
observed in the crystal structure. Thus, our photocrosslinking studies suggest that
N5-CAIR synthetase may exist in multiple dimer conformations.
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